TW320563B - - Google Patents

Download PDF

Info

Publication number
TW320563B
TW320563B TW081103293A TW81103293A TW320563B TW 320563 B TW320563 B TW 320563B TW 081103293 A TW081103293 A TW 081103293A TW 81103293 A TW81103293 A TW 81103293A TW 320563 B TW320563 B TW 320563B
Authority
TW
Taiwan
Prior art keywords
acid
fat
sugar
infusion
milk
Prior art date
Application number
TW081103293A
Other languages
Chinese (zh)
Inventor
Kazumasa Yokoyama
Original Assignee
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP03209947A external-priority patent/JP3097196B2/en
Priority claimed from JP3222031A external-priority patent/JP2950348B2/en
Application filed by Green Cross Corp filed Critical Green Cross Corp
Application granted granted Critical
Publication of TW320563B publication Critical patent/TW320563B/zh

Links

Landscapes

  • Medicinal Preparation (AREA)

Description

修正 !^-r· ' / -· .' ·.,ι 卜'二"‘ 補充 A 6 Π 6 320563 五、發明説明(1) 發明之辑 本發明偽親於輪液製劑待別係閼於包含糖,胺基 酸類,電解質類及脂肪乳液之输液製劑。裂劑具有卓越安 定性及儲存期。本發明也係關於裂造此等輸液製劑用之容 器,一種含脂防乳液及糖之输液製劑,及一種含胺基酸類 及電解質類之輸液製劑。 發明之背景 靜脈輸液於下列情·況下進行,俾提.供營養,維持病人的 生命:經口或經痒餓食為不可能或不足時,,病人之消化吸 收功能處在不良狀態,卽使可進行經口或經#餌食亦如此 時;或食物通過消化道,將使病人的情況或芪病更趨嚴重 時。 市面上可得之輸液製劑之例,包含糖输液,其中含有運 原糖等;胺基酸輸液,其中*含有必霈胺基酸類等;電解質 輸液,其中含有電解質類等;脂肪乳液,其中含植物油乳 液等;及维生素混合物。此等输液製劑可依據病人的情況 適當盏用,且於使用時溫合。 然而,於使用時混合此等製劑霖要複雜的.處置,尤其會 造成微生物污染問題。意圖克服此等問題,曾涇垮出事先 將若干前述成分混合在一起的各種翰液製劑。含有所有待 供應之必需養分,卽糖類,胺基酴類,電解質類,及脂肪 乳液類之输液製劑者由臨床觀點看來特別有用' 然而,由於此等耱液,胺基酸液,罨解質液,及脂昉乳 液之安定筷件彼此不同,因此,箪混ν合時,出現各種問題 (請先閲請背而之注意赛項再填筠本頁) 裝< 經濟部屮央標準局Α工消费合作社印Μ 姝浪Λ/t遑用中aa家樣準(α<5)Ή規格(210X297公; 繆 81. 4. 10,000ft. (Η) 320563 Λ 6 Π 6 五、發明説明(2 ) ,使得混合物無法用於多種情況。 舉例言之,脂肪乳液由於性質不安定,因此容易生成龐 大的脂肪粒子,當與其他輸液混合時,造成相分離(乳油 化現象)。特別,電解質輸液内之二價陽離子使得脂肪乳 液粒子凝結與崩散。 以電解質輸液為例,由於輸液中含有維持電解質平衡所 必需之鈣及磷酸,因此易因鈣與磷酸反應生成磷酸鈣而産 生混濁之沈澱。欲求防止混濁與沈澱之生成,通常將此種 電解質輸液調整為低pH值(低於ρΗ5)。當此種電解質輸液 與胺基酸輸液混合時,由於胺基酸之強力缓衝作用,使得 混合物之pH增高至胺基酸之pH值,因此需要大量酸性物料 (如氫氛酸,乙酸等),俾能將pH值維持於低水平。然而, 由於大量酸會破壞輸液組分之平衡,故僅能使用有限量之 酸性物料。結果,電解質與胺基酸輸液混合物之pH值無法 降至令人滿意的水平,因而導致混合物加熱滅菌時,出現 (請先閲請背而之注意事項冉填寫本頁) 裝· 訂_ 線· 經濟部屮央榣準局貝工消费合作杜印t , ,型 、肪待安 時 類同性脂期可 菌 質不變合 ,又 滅 解等 、混此時 熱 。電此離才因同 加象 ,合分時 。 , 藉現類混相用液液 物色酸於 、使輸乳 合著基咎澱於質肪 混著胺歸沈係解 之顯 ,像如常電及^-!' 液現糖 ,例通及 , 輸出有劑 , * ,質 糖 ,含製題題液解 與應 備液問 問輸 電 液反製輸種等酸 , 輸d)先存各此基酸 酸ar事儲起在胺基 基11以可引存 ,胺 。胺ai難之會於液 , 殺當(M,液液由輸糖 沈 ,勒述乳乳。糖有 與外梅前肪或等 ,含 濁此於如脂液色液種 混由 及輸著乳一 Λ 本紙张尺度边用中困國家榣毕(CNS)T4規格(2〗0χ297公¢) 81. 4. U),000張(H) 五、發明説明(3) 定儲存的輸液製劑。 發明之概要 鑑於此等 解質類,及 即使於含有全 分之性質, 變性、著色 又復,由 發現含有前 使用時,經 液製劑而未 提供含有 有卓越安定 目的。 情況,本 脂肪乳液 部組分之 及藉著其 等問題。 於對此等 述各組分 由將前述 遭遇沈·澱 糖,胺基 性,因而 Λ 6 Η 6 發明人對開發含有糖,胺基酸類,電 之安定輸液製劑進行徹底研究。發現 輸液製劑之例中,也可藉著改善各組 他修改而解決例如,沈澱、相分離、 輸液製劑之製法進行徹底研究,結果 之某種組合之製劑可安定地儲存,於 各製劑混合,可方便地獲得期望的輸 、變性、箸色,及其他問題。 酸類,電解質類,及脂肪乳液,且具 可安定儲存之輸液製劑乃本發明之一 (請先閲讀背而之注意事項#埸寫本頁) 裝· 訂- 經濟部屮央標準局员工消作合作杜印製 提供填充以输液製劑且可用於混合输液製劑之容器乃本 發明之另一目的。 提供一種含脂肪乳液及糖之輸液製劑乃本發明之又另一 目的。 · 提供一種含胺基酸類及電解質類之輸液製劑乃本發明之 另一目的。 附圖之簡述 '第1圖為供填充輸液製劑之本發明容器之一例之横斷面 圖。 第2圖為供填充輸液製劑之本發明容器之另一例之横斷 Λ 〆* t紙張尺度逍用中困國家標準(CNS) Ή規格(210X297公;«:) 81. 4. 10,_張.(H)Amendment! ^ -R · '/-·.' ·., Ι Bu 'II "' Supplement A 6 Π 6 320563 V. Description of the invention (1) Collection of inventions The present invention is pseudo-pro-to-round liquid preparation For infusion preparations containing sugar, amino acids, electrolytes and fat emulsions. The cracking agent has excellent stability and storage period. The present invention also relates to a container for cracking such infusion preparations, an infusion preparation containing a fat-proof emulsion and sugar, and an infusion preparation containing amino acids and electrolytes. BACKGROUND OF THE INVENTION Intravenous infusion is performed under the following circumstances to provide nutrition and maintain the patient's life: when oral or itching hunger is impossible or insufficient, the patient's digestive and absorption function is in a bad state. The same can be done when oral or Jing # bait; or when food passes through the digestive tract, will make the patient's condition or Qi disease more serious. Examples of infusion preparations available on the market include sugar infusions, which contain unrefined sugar, etc .; amino acid infusions, in which * contains mustard amino acids, etc .; electrolyte infusions, which contain electrolytes, etc .; fat emulsions, which contain Vegetable oil emulsion, etc .; and vitamin mixture. These infusion preparations can be used appropriately according to the patient's condition, and should be warm during use. However, mixing these formulations during use requires complicated handling, and in particular can cause microbial contamination problems. In order to overcome these problems, Zeng Jing broke out various liquid preparations in which several of the aforementioned ingredients were mixed in advance. Infusion preparations containing all the essential nutrients to be supplied, sucrose, amines, electrolytes, and fat emulsions are particularly useful from a clinical point of view. The stabilizing chopsticks of the liquid and the fat emulsion are different from each other. Therefore, various problems occur when mixing the slabs (please read the back of the contest first and then fill in the page). Install < the Ministry of Economic Affairs Standard Printed by the Bureau of Industry and Consumer Cooperatives 姝 浪 Λ / t 遝 鐘 home sample standard (α < 5) Ή specification (210X297; Miao 81. 4. 10,000ft. (Η) 320563 Λ 6 Π 6 V. Description of invention (2), making the mixture unusable in many situations. For example, fat emulsions are prone to generate large fat particles due to their unstable nature, and when mixed with other infusions, cause phase separation (emulsification). In particular, electrolytes Divalent cations in the infusion cause the fat emulsion particles to coagulate and disintegrate. Taking electrolyte infusion as an example, because the infusion contains calcium and phosphoric acid necessary to maintain electrolyte balance, it is easy to cause mixing due to the reaction of calcium and phosphoric acid to form calcium phosphate To prevent the formation of turbidity and Shendian, this electrolyte infusion is usually adjusted to a low pH value (lower than pH 5). When this electrolyte infusion is mixed with an amino acid infusion, due to the strong buffering effect of the amino acid , So that the pH of the mixture is increased to the pH of the amino acid, so a large amount of acidic materials (such as hydrochloric acid, acetic acid, etc.) are required to maintain the pH at a low level. However, because a large amount of acid will destroy the infusion components Balanced, so only a limited amount of acidic materials can be used. As a result, the pH value of the electrolyte and amino acid infusion mixture cannot be reduced to a satisfactory level, resulting in the mixture appearing when heated and sterilized (please read first, please pay attention Matters fill out this page) Install · Order _ Line · The Ministry of Economic Affairs, the Central Bureau of Economic Affairs, Beigong Consumer Cooperation Du Yint,, type, fat wait time, the same-sex fat period can not change the bacteria, and then eliminate, etc., It is hot at the time of mixing. The ionization is only due to the addition of the image, and the time is divided. The liquid mixture is used to find the acid, so that the lactation is based on the fat and mixed with the amine. , Like Ruchangdian and ^-! 'Liquid sugar , General information, output agent, *, quality sugar, containing the solution of the problem-solving problem and the preparation solution to ask the power transmission fluid to counter the seed and other acids, lose d) store the acid of this acid first. The amino group 11 can be deposited as an amine. The amine ai is difficult to get in the liquid, killing (M, the liquid liquid is precipitated by sugar, and the milk is described. The sugar is mixed with the outer plum or the fat, etc., the turbidity is mixed with the liquid such as the fat liquid and the transfer Ruyi Λ This paper scale is used in the middle-sleepy country (CNS) T4 specification (2〗 0 × 297 public ¢) 81. 4. U), 000 sheets (H) V. Description of the invention (3) The infusion preparation is scheduled to be stored. SUMMARY OF THE INVENTION In view of these decomposed types, and even if it contains all the properties, denaturation and coloration are repeated, it is found that the use of menstrual preparations before use is not provided with the content of excellent stability. The situation, the components of the fat emulsion and its problems. For these components, the inventors have encountered the aforementioned problems with the sugar and amino groups, and therefore, the inventors conducted a thorough study on the development of infusion preparations containing sugar, amino acids, and diazepam. Found examples of infusion preparations can also be solved by improving the modification of each group. For example, precipitation, phase separation, and infusion preparation methods are thoroughly studied. As a result, a combination of preparations can be stored safely and mixed with each preparation. Can easily get the desired loss, denaturation, color, and other problems. Acids, electrolytes, and fat emulsions, and infusion preparations with stable storage are one of the inventions (please read the back-end notes # 圸 写 此 页) Installation and Ordering-Staff of the Ministry of Economic Affairs Bureau of Standards It is another object of the present invention to provide containers filled with infusion preparations that can be used for mixing infusion preparations. It is another object of the present invention to provide an infusion preparation containing a fat emulsion and sugar. · It is another object of the present invention to provide an infusion preparation containing amino acids and electrolytes. BRIEF DESCRIPTION OF THE DRAWINGS 'Figure 1 is a cross-sectional view of an example of a container of the present invention for filling an infusion preparation. Figure 2 is a cross-section of another example of the container of the present invention for filling infusion preparations Λ 〆 * t paper-scale national standard (CNS) Ή specification (210X297 public; «:) 81. 4. 10, _ Zhang . (H)

V 經濟部屮央榣準局貝工消讣合作社印Μ ^20563 Λ 6 _Π_6_ 五、發明説明(4) ' 面圖。 第1及2圖中,參考數目1及11代表本發明容器,2及12代 表第一隔間,3及1 3代表第二隔間,4及1 4代表含脂肪乳液 類及糖類之輸液,5及15代表含胺基酸類及電解質類之輸 液,6代表連通器件,7及16代表分隔構件,而8,9,10, 1 7, 1 8及1 9代表開口。 第3圖為實施例3所得之脂肪乳液樣品之平均粒徑與該樣 品通過乳化器之次數之關偽圖。第3圖中,♦符號代表甘 油,♦代表葡萄糖,〇代表山梨糖醇,□代表木糖醇,▽ 代表果糖,及▲代表對照。 發明之細節說明 本發明係有關一種包含糖,胺基酸類,電解質類,及脂 肪乳液之输液製劑,該製劑以多元醇或糖之磔酸酯形式或 酯鹽形式含有磷,及藉有機酸將pH值調整為5 . 0至8本 發明也係關於填充以輸液之容器,其可用於混合輸液製劑 。又復,本發明偽有關一種含脂肪乳液及糖之输液製劑, 及含胺基酸類及電解質類之輸液製劑。 特別,較好使用平均粒徑為0 . 1 7 M m或以下之脂肪乳液 ,電解質之磷來源較好為多元醇或糖之磷酸酯或酯鹽。 本發明之填充以輸液之容器,為其中包括由一分隔構件 所隔開的第一及第二隔間之容器。含脂肪乳液及糖之輸液 含於第一隔間内,而含胺基酸類及電解質類之另一輸液含 於第二隔間内。 各類型糖類皆可用於本發明。·還p糖如葡萄糖,果糖 ·: \ (請先閲請背而之注念事項再填寫本頁) 本紙张尺度逍用中8困家榣华(CNS)例規格(210X297公幻 81. 4. 10,000張(H) Λ 6 Π 6 五、發明説明(5 ) ,麥芽糖等為特佳。此等還原糖類可單獨使用或呈兩種或 兩種以上之混合物形式使用。此等還原糖類又可與選自山 梨糖醇,木糖醇、甘油等中之至少一種化合物混合。 本發明所用之胺基酸類之例包含各種必需及非必需胺基 酸,其曾用於習知胺基酸輸液製劑以提供活體營養素者, 例如L-異白胺酸,L-白胺酸,L-纈胺酸,L-離胺酸,L-蛋 胺酸,L-苯基丙胺酸,L-酥胺酸,L-色胺酸,L-精胺酸, L -組胺酸,甘胺酸,L -丙胺酸,L -脯胺酸,L -天冬胺酸, L-絲胺酸,L-酪胺酸,L-麩胺酸,L-半胱胺酸等。此等胺 基酸不僅可呈游離胺基酸形式使用,同時也可以多種其他 形式使用,例如包含:無機酸鹽,如L -離胺酸鹽酸鹽等; 有機酸鹽,如L -離胺酸乙酸鹽,L -離胺酸順丁烯二酸鹽等· ;可於活體内水解之酯類,例如L-酪胺酸甲酯,L-蛋胺酸 甲酯,L -蛋胺酸乙酯等;Ν -取代衍生物,如Ν -乙菌基- L-色胺酸,Ν-乙醯基-L-半胱胺酸,Ν-乙醯基-L-脯胺酸等; 及相同或相異胺基酸所生成之二肽,如L -酪胺醛基-L -酪 胺酸,L-丙胺醯基-L-酪胺酸,L-精胺醯基-L-酪胺酸,L- 經濟部中央梂準局员工消伢合作杜印製 等 酸 胺 精 I L 導 基 m 胺 酪 明鹽 發酸 本糖 作萄 用葡 可 , 鹽鹽 性酸 溶乙 水 , 型鹽 各酸 之硫 劑 , 製物 液化 輸氣 術含 技包 前 , 先類 於質 用解 曾電 之 鎂持 ,維 鈣内 , 體 鉀活 , 於 納為 如鹽 鹽等 性此 溶 , 水鹽 之等 分磷 組 , 機碘 無 , 種錳 各 , ; 銅 等 , 鹽鐵 酸 , 乳鉾 0 性 溶 水 等 此 用 使 可 也 ο 者 0 必 所 衡 平 質 解 電 。 與物 能合 功水 物之 生類 本紙張尺度边用中國Η家標準(CN5)規格(210x297公龙) \ 81 乂 10,000張(Η) Ϊ »_\\ i .. • · · · .-V · ·..........【......裝:.·訂.·:線.....f.....··.*.. (請先閲請背而之注意事項再填寫本頁) 經濟部屮央描準局貝工消贤合作社印^ 320563 Λ 6 ___Π6_ 五、發明説明(6 ) 於此等電解質組分中,可適當使用多元醇或糖之磷酸酯 類或其鹽作磷來源。多元醇之磷酸酯類之例包含甘油基磷 酸,甘露糖醇--磷酸,山梨糖醇-卜磷酸等。糖類之磷酸 酯類之例,包含Μ萄糖-6-磷酸,甘露糖-6-磷酸等。至於 此等磷酸酯之鹽類,可使用鹼金屬鹽類,如銷鹽,鉀鹽等 ,.及鹼土金屬鹽類,如鎂鹽。磷酸酯鹽類之較佳例為甘油 * 基磷酸之鈉鹽與鉀鹽。 較佳電解質組分如下: 鈉:氛化鈉.,乳酸鈉,乙酸m,硫酸鈉,及甘油基磷酸 鈉; 鉀:氯化鉀,甘油基磷酸鉀,硫酸鉀,乙酸鉀,及乳酸 鉀; 、 鈣:葡萄糖酸鈣,氯化鈣,甘油基磷酸鈣,乳酸鈣,泛 酸鈣,及乙酸鈣; 鎂:硫酸鎂,氣化鎂,甘油基磷酸镁,乙酸鎂,及乳酸m ; 磷:甘油基磷酸鉀,甘油基磷酸鈉,甘油基磷酸鎂,及 甘油基磷酸鈣;及 鋅:硫酸鋅,氣化鋅,葡萄糖酸鋅,乳酸鋅,及乙酸鋅。 本發明之脂肪乳液可為油於水型乳液,此乳液之製法偽 使用乳化劑將脂肪分散於水中。脂肪乳液可以任一種適當 方式製備,例如將脂肪及乳化劑加入水中,攪拌混合物而 製得粗乳液,然後,藉任何常用手段,如高壓乳化法將粗 乳液乳化。 (請先閱讀背而之注意事項再填寫本頁) 本紙ft尺度边用中國國家楳準(CNS)TM規格(210X297公放) 81. 4. 10,000張(H) Λ 6 Π 6 經濟部屮央櫺準局ex工消设合作杜印製 五、發明説明(7 ) 當藉高壓乳化法製備乳液時,粗乳液可於通常由20至 7 0 0kg /era2之壓力條件下通過均化器,如曼頓-高林 (Manton-Gaulin)均化器,5至 50 次。 任一種食用脂肪及油類皆可用作脂肪乳液及脂肪來源。 脂肪來源之較佳例包含:植物油如大豆油,棉子油,红花 籽油,玉米油,椰子油,紫蘇油等;魚油如鱈魚肝油等; 中鏈脂肪酸三酸甘油酯,如PanaceU商品名),0D0 (商品 名)等;及化學精練之三酸甘油酯如2 -亞油·醯基-1,3 -二辛 酸甘油酯(8L8), 2 -亞油醯基-1,3 -二癸酸甘油酯(10L10) 等。此等脂肪類及油類可單獨使用,或呈兩種或兩種以上 之混合物形式使用。 藥物製劑常用之任一種乳化劑皆可用於本發明。可用一 種或一種以上之化學劑,較好選自卵黃磷脂類,氫化卵黃 磷脂類,大豆磷脂類,氫化大豆磷脂類,及非離子界面活 性劑,如普隆尼(Plu「〇niC)F68(商品名,聚環氣乙烷聚環 氧丙烷嵌段共聚物)及HC〇-60(商品名,聚氧次乙基氫化蓖 麻油)。 以由使用大豆油作脂肪來源及卵.黃磷脂作乳化劑製得之 脂肪乳液為特佳。 依據本發明,脂肪乳液之製法較好使其平均粒徑變成 0 . 1 7 w m或以下。藉由將粒子直徑控制於此水平,可獲得 比較目前使用之脂肪乳液(平均粒徑,0 . 2至0 . 3 μ π )之安 定度更髙的脂肪乳液,因而可有效預防由於比重差異所引 起之.脂肪乳液内相分離。 、 (請先閲讀背而之注意事項#填寫本頁) 卜紙張尺度边用中3困家標準(CNS) Τ4規格(210X297公*) :α·\ 81, 4. 10,000張(Η) 經濟部屮央櫺準局貝工消费合作社印製 五、發明説明(8 ) 平均粒徑為0 . 1 7 ;α π或以下之脂肪乳液可經由將選自甘 油及葡萄糖中之至少一種化合物加入其中,接著進行乳化 而製備。依據此種技術,由於甘油及葡萄糖對促進細粒生 成具有待定能力之故,可方便製備平均粒徑為0 . 1 7 w a或 以下之脂肪乳液。 進一步示例說明,此種脂肪乳液之製法,例如藉由將脂 肪來源及乳化劑連同甘油及/或葡萄糖加入水中,攪拌混 合物,獲得粗乳液,然後藉習知方法,例如前述高壓乳化 法乳化粗乳液。此種情況下,可於乳化之時添加甘油及/ 或葡萄糖。例如,甘油及/或葡萄糖可加入由脂肪及乳化 劑所製得之粗乳液内。 由此製得之乳液之平均粒徑可藉習知方法,如光繞射法 測定。 前述乳液製法中,脂肪,乳化劑及甘油及/或葡萄糖之 用量,使得所生成之脂肪乳液之組成為脂肪含量由0.1至 3 0 %,以w / ν計(除非有其他陳述,否則後文所用之” % ” 一詞 代表w/v%),較好由1至20%;乳化劑含量為0.01至10¾,較 好由0.05至5%;甘油及/或葡萄糖含量為30至70%,較好由 40至60¾ ;及適量水。 本發明之輸液製劑内所含之糖類,胺基酸類,電解質類 ,及脂肪乳液類之混合比與濃度可依製劑之用途,病人之 疾病與症狀,及其他條件調整。下文示例說明本~發明之輸 液製劑之較佳組成: 脂肪乳液及糖: (請先閱讀背而之.注意事項再蜞寫本頁) 本紙张尺度边用中SS家楛準(CNS)>H規格(210X297公¢) V 81 4 10 000張(H) Λ 6 Π 6 經濟部屮央榀準局员Η消伢合作杜印製 五、發明説明(9 ) 脂 肪 5-50 g/儿 乳 化 劑 0.5-10 g/λ 糖 50-250 g/Ji ί基 酸 類 及 電 解質 類: L- 異 白 胺 酸 0 . 5 _ 5 g /儿 L-白胺酸 0.5-7 g /义 L- 織 胺 酸 0.5-5 g /义 L - 離 胺 酸 0.5-7 g/义 L- 蛋 胺 酸 0.1-4 g /义 L- 苯 基 丙 胺 酸 0 · 3 - 5 g /艾 L- 酥 胺 酸 0.3-5 g / JL L- 色 胺 酸 0.1-1 g / iL L- 精 胺 酸 0.3-7 g /义 内 胺 酸 0.2-3 g / il :.v4 泔胺酸 0.2-3 g / JL -:Γ^ ίΐί 丙 胺 酸 0.3*5 g/il 3脯 胺 酸 0.2-5 g/il L- 天 冬 胺 酸 0.03-2 g / JL L- 絲 胺 酸 0 . 2 ~ 3 g / JL L- 酪 胺 酸 0 . 0 3 ~ 0 . 5g/JL L- 麩 胺 酸 0.03-2 g / iL L- 半 胱 胺 酸 0.03-1 IB E q / JL 納 15-60 ffl E q / JL 鉀 10-50 Bl E q / JL m 3-15 ffl E q / liL 本紙张尺度边用中囷S家標準(CNS)甲4規格(210X297公没) (請先閲,·*·,?背而厶注意事項洱蜞莴本頁) 裝· 線- 8】.6. 10,000張(Η) 320563 Λ Π 6 經β部屮央榀準局β工消费合作杜印製 五、發明説明(U)) m 2 - 10 Π1 Eq /义 氨 8 - 80 ΙΠ Eq /文 磷 1 - 15 m Eq /义 鉾 0 - 30 μταοί / iL 本 發 明 之 輸 液 製 劑 之 製 法 可 藉 由; 將 前 述 各 組 分 溶 解 於 或 分 散 於 純 水 (例如, 注条 ί用蒸餾水等 " 内 > 或 者 較 好 藉 由 値 別 製 傭 糖 液 » 胺 基 酸 液 t 電 解 質 液 及 脂 肪 乳 液 將 如 此 所 製 得 之 各 液 滅 菌 t 及 藉 加 熱等進行乳 化 f 隨 後 t 以 無 菌 方 式 混 合 滅 菌 後 之 输 液 及 乳 液 9 而 其 混 合 比 偽 可 將 各 組 分 濃 度 調 整 至 預 定 水 平 者 0 糖 液 t 胺 基 酸 液 > 及 電 *71 m- 質 液 可 以 習 知 方 式 製 備 而 脂 肪 乳 液 可- 藉 一 刖 述 方 法 製- 備 0 如 此 f 所 製 得 之 各 輸 液 及 乳 液 置 於 玻 璃 或 塑 膠 容 器 内 〇 容 器 内 之 氛 圍 以 惰 氣 如 氮 氪 等 置 換 1 然 後 密 封 該 容 器 t 及 進 行 適 當 滅 菌 處 理 0 此 例 中 » 玻 璃 或 塑 膠 容 器 可 呈 袋 形 、 瓶 形 等 > 其 材 料 有 聚 丙 烯 、 聚 乙 烯 、 乙 烯 -乙酸乙烯酯共聚物。 聚氯乙烯等。 滅菌 過 程 可 以 常 見 方 式 進 行 > 例 如 緖 加 熱 滅 菌 處 理 如 高 壓 水 蒸 氣 滅 菌 t 熱 水 浸 漬 滅 菌 > 熱 水 淋 洒 滅 菌 等 〇 當 使 用 塑 膠 容 器 時 較 好 於 大 體 不 含 氧 之 氛 圍 中 進 行 滅 菌 〇 依 本 發 明 填 充 以 輸 液 之 容 器 包 括 一 密 封 容 器 其 中 包 括 可 經 由 連 通 器 件 彼 此 連 通 的 二 隔 間 〇 此 二 隔 間 利 用 附 著 於 連 通 器 件 之 一 分 隔 構 件 彼 此 隔 開 〇 含 脂 肪 乳 液 及 糖 之 輸 注 液 封 於 第 一 隔 間 内 > 而 含 胺 基 酸 類 及 電 解 質 類. 之 另 一 輸 液 封 於 第 二 隔 間 内 % 接 著 即 刻 進 行 加 ,熱- - .'· ι .;"(i 菌 〇 使 用 時 9 經 由 本紙張尺度逍用中8國家標準(CNS)甲4規格(210x297公放) 81. 4. 10,000張(H) (請先閱請背而之注意事項#项寫本頁) Λ 6 Π 6 經濟部屮央梂準局貝工消费合作社印驭 五、發明説明(11) 撤離分隔構件,允許第一及第二隔間彼此連通,因而經由 連通器件混合二液體,而製得輸液製劑。 第1圖為横斷面圖,顯示本發明之填充以輸液之容器之 一例。本圖中,塑膠材料製之容器1具有二隔間,亦即第 一隔間2,及第二隔間3,含有脂肪乳液及糖之輸液4容纳 於第一隔間2内,而另一者含胺基酸類及電解質類之輸液5 容納於第二隔間3内。第一及第二隔間2及3,利用附箸於 連通器件6之分隔器件7(本例為扣緊栓)彼此分隔,俥避免 第一隔間2所含之輸液4與第二隔間3所含之輸液5混合。此 外,容器設有一開口 8供輸液4注入第一隔間2内,開口 9供 輸液5注入第二隔間3内,及開口 10供射出混合後之製劑之 用。若有所需,可經由此等開口進行其他化學劑之混合。 填充以輸液之此種容器係以下述方式獲得。首先,藉分 隔構件(本例為扣緊栓7)封閉容器1之連通構件6,而將第 一及第二隔間2與3彼此隔開,接著將含脂肪乳液及糖之輸 液經由開口 8注入第一隔間2内,及將含胺基酸類及電解質 類之另一輸.液經由開口 9注入第二隔間3内。此種情況下, 較好於惰氣,如氮,氬等氣流.下進行輸液4及5之注入第一 及第二隔間2及3内。當輸液4及5注入第一及第二隔間2及3 完成時,開口 8及9經密封,所生成之容器經滅菌,而得第 1圖之封有輸液之容器。滅菌可以任一種習知手段進行, 舉例言之,藉由加熱滅菌手段,如高壓水蒸氣滅菌,熱永 浸没滅菌,熱水淋洒滅菌等。當塑膠容器用於此等情況時 ,較好於大體不含氧之氛圍下進行之滅菌。 (請先閲讀背而之注意事項再填寫本頁) 本紙5Jc尺度遑用中a Η家標準(CNS)肀4規格(210x297公放) 81. 4.】0,000張(Η) 經濟部屮央榀準局貝工消费合作杜印51 320563 Λ _Π6_ 五、發明説明α2) 如此所得之本發明之封有輸液的.容器可就此儲存。含脂 肪乳液、糖、胺基酸類,及電解質類之輸液製劑可於使用 時,藉移開扣緊'栓7,令第一及第二隔間2及3彼此連通, 並使各隔間内所封之輸液4及5混合,而進行無菌混合。隨 後,如此混合後之輸液製劑以無菌方式由開口 1 0射出,及 經由管(圖中未示)投予活體。 第2圖為横斷面圖,顯示本發明之填充以輸液之容器之 另一例。本圖中,由塑膠材及其他材料製成之矩形容器11 具有二隔間,亦即第一隔間1 2及第二隔間1 3 ,二者藉一大 螺栓1 6彼此分隔。含脂肪乳液及糖之輸液1 4封於第一隔間 12内,而含胺基酸類及電解質頚之另一輸液15封於第二隔 間1 3内。由於第一及第二隔間1 2及1 3傺藉螺栓1 6彼此分隔 ,故對於第一隔間1 2内之輸液1 4與封於第二隔間1 3内之輸 液15並未混合。此外,容器11設有一開口 17供將輸液14注 入第一隔間1 2用,開口 1 8供將輸液1 5注人第二隔間1 3用, 及開口 19供射出混合後的製劑之用。若有所需,可經由’此 等開口進行其他化學劑之混合。第2圖所示填充以輸液之 容器之製法及用法,大體與第1圖所示之容器相同。輸液 14, 15之混合像藉著旋開螺栓16而完成。 第1及2圖所示之封有輸液之容器僅屬本發明之一主題, 而不得視為限制本發明之範圍。容器之形狀、大小等可自 由改變,分隔構件亦如此。舉例言之,於第1圖中,可使 用夾子取代扣緊栓7,或第一與第二隔間2與3可藉著於連 通構件6内裝設一球栓而彼此分隔。$可使用可熱熔膜或 (請先閲讀背而之注意事項再填寫本頁) 本紙張尺度边用中a國家榀準(CNS)f 4規格(210X297公龙) 81. 4_ 10,000張(H) x. '»mJu\ Λ fi 1? 6 濟 部 中 央 準 Μ 工 消 合 社 印 五、發明説明(13) 可裂式連接.器。 . 前述製程中,有待封於第一隔間内之含脂肪乳液及糖之 輸液可藉多.種手段製備。舉例言之,糖可加入事先藉前述 程序製得之脂肪乳液内,或加入有待乳化之脂肪/乳化_ 混合物内。較好,於脂肪乳液製備時,將瑭加入脂肪内, 使得脂肪乳液之平均粒徑變成0 . 1 7 w m或以下。此種脂肪 乳液可如前述製備。含脂肪乳液及糖之輸液之組成可依有 待封於第二隔間内之輸液(換言之,含胺基p類及電解質 類之輸液)之濃度·,有待注入第一及第二隔間之输液體積 比等任意改費。組成之-較佳例包含脂防含量由0 . 1至3 0 3:, 較好由1至201,更好由2至10¾,乳化劑含量电0.01至10¾ ,較好由0.05至53:,更好由0.1至1%,還原糖之含量:由5至 60S:,較好由7至404,更好由10至3.031,及適最的水。 有待封於第二隔·間肉之含-胺基酸類及電解質類之输液可 藉各種手段製備。舉例言之,有待摻混之各胺基酸及電解 質可溶解於純水,如注射用蒸餾水内。含族基酸類及轚解 質類之输液組成可依有待封於第一隔間内之輸液(亦6P含 脂肪乳液及糖之輸液)之漤度,有待注入第一及第二隔間 内之輸液之髏稹比等任意改變。組成之一較佳例包含胺基 酸總量由1至15¾.較好由2至13¾,更好由3至12Λ;以及至 於電解質為50至180nEq/il鈉,40至135inEq/Jl鉀,10至50 ’ nEs/义鈣,5 至 30oiEq /义鎂,0 至 225nEq /文氯,3 至 40nEq/ 文磷及0至1 0 0jwmol/儿鋅,此外為適置.的水。 、 較佳組成如下: / 1¾ 請 背 意 事 3R -Pl· 填 寫· 本/ 頁 裝 η 線 本紙汝尺度ϋ用中SS家榀準(CNS)T4規«S(210x297公龙} 聲正11 81- 4. ]0,000ft(B) Λ 6 Π 6 經濟部屮央標準局貝工消费合作杜印製 五、發明説明(14) 電解質 類 - 鈉 50 -180 m E q / iL 鉀 40 -135 m E q / 义 鈣 10 -50 nj E q / 义 m 5 -30 Π! E q / JL 氮 0 -225 rn E q / A_ 磷 3 -4 0 ID E q / 义 鋅 0 -100 户mol /义 胺基酸 類 L-異 白 胺 酸 1-15 g / iL L-白 胺 酸 1-20 g/儿 L-纈 胺 酸 1-15 g / il L-離 胺 酸 鹽 酸 鹽 1-20 g/il L·-蛋 胺 酸 0 .5-10 g / Jl L -苯 基 丙 胺 酸 1-15 g/il- L-酥 胺 酸 1-15 g/il L-色 胺 酸 0 • 3-3 g/il L-精 胺 酸 1-20 g /义 組 | . 一 Y · ! 胺 酸 0 .5-10 g/il l· ϋ甘 U·. 胺 酸 0 .5-10 g / A. 丙 胺 酸 1-15 g / iL L-脯 胺 酸 0 • 5-15 g / JL L-天 冬 胺 酸 0 .1-5 g/il L _絲 胺 酸 0 .5-10 g/ilV Printed by the Beigong Bureau of the Ministry of Economic Affairs, the Beigong Consumers ’Cooperative Society ^ 20563 Λ 6 _Π_6_ V. Description of the invention (4) 'Plan view. In figures 1 and 2, reference numbers 1 and 11 represent the container of the present invention, 2 and 12 represent the first compartment, 3 and 13 represent the second compartment, 4 and 14 represent the infusion containing fat emulsions and sugars, 5 and 15 represent infusions containing amino acids and electrolytes, 6 represents a communication device, 7 and 16 represent a partition member, and 8, 9, 10, 1 7, 18 and 19 represent openings. Figure 3 is a pseudo-graph of the relationship between the average particle size of the fat emulsion sample obtained in Example 3 and the number of times the sample passed through the emulsifier. In Figure 3, ♦ stands for glycerin, ♦ stands for glucose, ○ stands for sorbitol, □ stands for xylitol, ▽ stands for fructose, and ▲ stands for control. The details of the invention indicate that the present invention relates to an infusion preparation containing sugar, amino acids, electrolytes, and fat emulsion. The preparation contains phosphorus in the form of an ester or salt of a polyhydric alcohol or sugar. The pH value is adjusted to 5.0 to 8. The present invention also relates to a container filled with infusion, which can be used for mixing infusion preparations. Again, the present invention pseudo relates to an infusion preparation containing fat emulsion and sugar, and an infusion preparation containing amino acids and electrolytes. In particular, it is preferred to use a fat emulsion having an average particle size of 0.17 mm or less, and the phosphorus source of the electrolyte is preferably a phosphate or ester salt of a polyhydric alcohol or sugar. The container filled with infusion of the present invention is a container including first and second compartments separated by a partition member. The infusion containing fat emulsion and sugar is contained in the first compartment, and the other infusion containing amino acids and electrolytes is contained in the second compartment. Various types of sugars can be used in the present invention. · Return sugars such as glucose and fructose ·: \ (Please read the back-notes and fill in this page first) This paper scale is used in 8 sleepy homes (CNS) example specifications (210X297 公 幻 81. 4 . 10,000 sheets (H) Λ 6 Π 6 V. Description of the invention (5), maltose, etc. are particularly preferred. These reducing sugars can be used alone or in the form of a mixture of two or more. These reducing sugars can also be used. It is mixed with at least one compound selected from sorbitol, xylitol, glycerin, etc. Examples of amino acids used in the present invention include various essential and non-essential amino acids, which have been used in conventional amino acid infusion preparations To provide living nutrients, such as L-isoleucine, L-leucine, L-valine, L-lysine, L-methionine, L-phenylalanine, L-melamine , L-tryptophan, L-arginine, L-histidine, glycine, L-alanine, L-proline, L-aspartate, L-serine, L-casein Amino acids, L-glutamic acid, L-cysteine, etc. These amino acids can be used not only in the form of free amino acids, but also in many other forms, including for example: inorganic acid salts, L-ionine hydrochloride, etc .; organic acid salts, such as L-ionine acid acetate, L-ionine acid maleate, etc .; esters that can be hydrolyzed in vivo, such as L-tyrosine Methyl methionate, methyl L-methionine, ethyl L-methionine, etc .; N-substituted derivatives, such as N-ethinyl-L-tryptophan, N-acetyl-L-half Cysteine, N-acetyl-L-proline, etc .; and dipeptides generated from the same or different amino acids, such as L-tyramine-aldehyde-L-tyrosine, L-propylamine -L-tyrosine, L-spermine acetyl-L-tyrosine, L-Ministry of Economic Affairs, Central Bureau of Economic Affairs, employees of the Ministry of Economic Cooperation cooperated to produce and print other acid amine sperm IL lead group m tyramine salt hair acid sugar It is used as grapevine, salt-salt acid-soluble ethyl water, sulfur agent for various salts of acids. Before the preparation of liquefied gas delivery technology, it should be similar to the quality of the magnesium solution used in the solution. Potassium activity, Yu Na is an isotropic solution such as salt and salt, water and salt are equally divided into phosphorus groups, organic iodine is not available, various kinds of manganese, copper, etc., salt ferric acid, milk and so on. ο The person 0 must balance the quality of electricity. The paper of this kind is the Chinese standard (CN5) standard (210x297 male dragon) \ 81 10,000 pieces (Η) Ϊ »_ \\ i .. • · · · -V · · .. ........ 【...... 装 :. · 定. ·: 线 。.... f ..... ··. * .. (Please read first, please pay attention Please fill in this page for details) Printed by Beigong Xiaoxian Cooperative of the Ministry of Economic Affairs of the Ministry of Economic Affairs ^ 320563 Λ 6 ___ Π6_ V. Description of the invention (6) In these electrolyte components, the phosphate esters of polyhydric alcohols or sugars can be used appropriately Or its salt as a source of phosphorus. Examples of phosphate esters of polyhydric alcohols include glyceryl phosphoric acid, mannitol-phosphoric acid, sorbitol-phosphoric acid, and the like. Examples of phosphate esters of sugars include glucose-6-phosphate, mannose-6-phosphate, and the like. As for the salts of these phosphate esters, alkali metal salts such as potassium salts, potassium salts, etc., and alkaline earth metal salts such as magnesium salts can be used. Preferred examples of phosphate ester salts are the sodium and potassium salts of glycerol * based phosphoric acid. The preferred electrolyte components are as follows: Sodium: sodium nitrate, sodium lactate, acetate m, sodium sulfate, and sodium glycerophosphate; potassium: potassium chloride, potassium glycerophosphate, potassium sulfate, potassium acetate, and potassium lactate;, Calcium: calcium gluconate, calcium chloride, calcium glyceryl phosphate, calcium lactate, calcium pantothenate, and calcium acetate; magnesium: magnesium sulfate, vaporized magnesium, glyceryl magnesium phosphate, magnesium acetate, and lactate m; phosphorus: glyceryl Potassium phosphate, sodium glyceryl phosphate, magnesium glyceryl phosphate, and calcium glyceryl phosphate; and zinc: zinc sulfate, vaporized zinc, zinc gluconate, zinc lactate, and zinc acetate. The fat emulsion of the present invention may be an oil-in-water emulsion. The preparation method of this emulsion pseudo-uses an emulsifier to disperse the fat in water. The fat emulsion can be prepared in any suitable manner, for example, fat and emulsifier are added to water, and the mixture is stirred to prepare a coarse emulsion, which is then emulsified by any common means, such as high-pressure emulsification. (Please read the precautions before filling in this page) The ft scale of this paper uses the Chinese National Standard (CNS) TM specifications (210X297 public) 81. 4. 10,000 sheets (H) Λ 6 Π 6 Ministry of Economic Affairs The quasi-bureau bureau co-operates with the industrial and commercial enterprises to make the printing. 5. Description of the invention (7) When the emulsion is prepared by the high-pressure emulsification method, the crude emulsion can pass through a homogenizer under a pressure condition of usually 20 to 700 kg / era2, such as Manton-Gaulin homogenizer, 5 to 50 times. Any kind of edible fat and oil can be used as fat emulsion and fat source. Preferred examples of fat sources include: vegetable oils such as soybean oil, cottonseed oil, safflower seed oil, corn oil, coconut oil, perilla oil, etc .; fish oils such as cod liver oil, etc .; medium chain fatty acid triglycerides, such as PanaceU trade name ), 0D0 (trade name), etc .; and chemical refining of triglycerides such as 2-linolein · acyl-1,3-dioctanoic acid glyceride (8L8), 2-linoleinyl-1,3--2 Glyceryl caprate (10L10), etc. These fats and oils can be used alone or as a mixture of two or more. Any emulsifier commonly used in pharmaceutical preparations can be used in the present invention. One or more chemical agents can be used, preferably selected from egg yolk phospholipids, hydrogenated egg yolk phospholipids, soybean phospholipids, hydrogenated soybean phospholipids, and nonionic surfactants, such as Plu "〇niC" F68 ( Trade name, polycyclic gas ethane polypropylene oxide block copolymer) and HC〇-60 (trade name, polyoxyethylene hydrogenated castor oil). To use soybean oil as a fat source and egg. Yellow phospholipid Fat emulsions prepared by emulsifiers are particularly preferred. According to the present invention, the preparation method of fat emulsions is preferably such that the average particle diameter becomes 0.17 wm or less. By controlling the particle diameter at this level, it is possible to obtain a comparatively current use The fat emulsion (average particle size, 0.2 to 0.3 μ π) is more stable than the fat emulsion, which can effectively prevent the phase separation of the fat emulsion caused by the difference in specific gravity., (Please read the back And the matters needing attention # fill in this page) BU3 Standard 3 Standards (CNS) Τ4 specifications (210X297 g *): α · \ 81, 4. 10,000 sheets (Η) Ministry of Economic Affairs Printed by the industrial and consumer cooperatives V. Description of invention (8) Average grain 0.17; fat emulsion of α π or below can be prepared by adding at least one compound selected from glycerin and glucose, followed by emulsification. According to this technique, glycerin and glucose have For the purpose of determining the capacity, it is convenient to prepare fat emulsions with an average particle size of 0.17 wa or less. Further examples illustrate the preparation of such fat emulsions, for example by adding fat sources and emulsifiers together with glycerol and / or glucose Stir the mixture in water to obtain a coarse emulsion, then emulsify the coarse emulsion by conventional methods, such as the aforementioned high-pressure emulsification method. In this case, glycerin and / or glucose can be added at the time of emulsification. For example, glycerin and / or glucose can be added In the coarse emulsion prepared from fat and emulsifier. The average particle size of the emulsion thus prepared can be determined by a conventional method, such as the light diffraction method. In the aforementioned emulsion preparation method, fat, emulsifier and glycerin and / or The amount of glucose is such that the composition of the resulting fat emulsion is from 0.1 to 30% fat content in terms of w / ν (unless otherwise stated, otherwise The term "%" used hereinafter means w / v%), preferably from 1 to 20%; the emulsifier content is from 0.01 to 10¾, preferably from 0.05 to 5%; the glycerin and / or glucose content is from 30 to 70 %, Preferably from 40 to 60¾; and an appropriate amount of water. The mixing ratio and concentration of the sugars, amino acids, electrolytes, and fat emulsions contained in the infusion preparation of the present invention may depend on the use of the preparation, the disease and Symptoms, and other condition adjustments. The following examples illustrate the preferred composition of the infusion preparation of the present invention: Fat emulsion and sugar: (Please read it first. Precautions before writing this page) This paper is used in SS home Standard (CNS) > H specification (210X297cm) V 81 4 10 000 sheets (H) Λ 6 Π 6 Co-authored by the quasi-bureau bureau of the Ministry of Economic Affairs, H. Co., Ltd. Printed by V. Invention description (9) Fat 5-50 g / children emulsifier 0.5-10 g / λ sugar 50-250 g / Ji base acids and electrolytes: L-isoleucine 0. 5 _ 5 g / children L-leucine 0.5-7 g / Sense L-Weinoic acid 0.5-5 g / Sense L-Ionic acid 0.5-7 g / Sense L-methionine 0.1-4 g / Sense L-phenylalanine 0 · 3- 5 g / Ai L-threonine 0.3-5 g / JL L- tryptophan 0.1-1 g / iL L- arginine 0.3-7 g / synonine 0.2-3 g / il: .v4 swill Alanine 0.2-3 g / JL-: Γ ^ ίΐί alanine 0.3 * 5 g / il 3 proline acid 0.2-5 g / il L-aspartic acid 0.03-2 g / JL L- serine 0. 2 ~ 3 g / JL L-tyrosine 0.03 ~ 0.5g / JL L-glutamic acid 0.03-2 g / iL L-cysteine 0.03-1 IB E q / JL Na 15-60 ffl E q / JL Potassium 10-50 Bl E q / JL m 3-15 ffl E q / liL This paper size is used in the middle of the S standard (CNS) A 4 specifications (210X297 public) (please read first, * · ,? (Notes on the back page of Erhu Lettuce) (Package · Line-8) .6. 10,000 sheets (Η) 320563 Λ Π 6 Printed by the β Department of the Central Bureau of Industry and Commerce β-consumer cooperation 5. The description of the invention (U )) m 2-10 Π1 Eq / Yi ammonia 8-80 ΙΠ Eq / Wen phosphorus 1-15 m Eq / Yi Fei 0-30 μταοί / iL The infusion preparation of the present invention can be prepared by; dissolving the aforementioned components In or dispersed in pure water (for example, distilled water etc. for "Notes", "internal") or preferably by making sugar liquids separately »Amino acid liquid t Electrolyte liquid and fat emulsion Sterilize t and emulsify by heating, etc. f Then aseptically mix the sterilized infusion and emulsion 9 and their mixing ratio can be adjusted to the predetermined level of each component. 0 Sugar solution t Amino acid solution> and electricity * 71 m- liquid can be prepared by conventional methods and fat emulsion can be-borrowed Prepared by the method described-Preparation 0 The infusions and emulsions prepared in this way are placed in glass or plastic containers. The atmosphere in the container is replaced with inert gas such as nitrogen krypton, etc. 1 The container is then sealed and properly sterilized. 0 This example Medium »Glass or plastic containers can be bag-shaped, bottle-shaped, etc.> The materials are polypropylene, polyethylene, ethylene-vinyl acetate copolymer. Polyvinyl chloride, etc. The sterilization process can be carried out in a common way> For example, heat sterilization Treatments such as high-pressure steam sterilization t hot water immersion sterilization > hot water spray sterilization, etc. 〇 Sterilize in a substantially oxygen-free atmosphere when using plastic containers. The container filled with infusion according to the present invention includes a sealed container It includes two compartments that can communicate with each other via a communication device. The two compartments are separated from each other by a partition member attached to the communication device. Fat contains The infusion solution of emulsion and sugar is sealed in the first compartment > and contains amino acids and electrolytes. The other infusion solution is sealed in the second compartment and then immediately added, heat--.. ι.; " (i fungus 〇 when using 9 through this paper standard for ease of use in the 8 national standard (CNS) A 4 specifications (210x297 public release) 81. 4. 10,000 sheets (H) (please read the notes before you please # Item write this page) Λ 6 Π 6 Ministry of Economic Affairs, Central Bureau of Industry and Economics, Beigong Consumer Cooperatives, Yinyu V. Description of the invention (11) Evacuation of the partition member, allowing the first and second compartments to communicate with each other, thus mixing two via the connecting device Liquid, and prepared infusion preparation. Figure 1 is a cross-sectional view showing an example of a container filled with infusion according to the present invention. In this figure, a container 1 made of plastic material has two compartments, namely a first compartment 2 and a second compartment 3, an infusion 4 containing fat emulsion and sugar is contained in the first compartment 2, and another The infusion 5 containing amino acids and electrolytes is contained in the second compartment 3. The first and second compartments 2 and 3 are separated from each other by a separating device 7 (in this example, a fastening bolt) attached to the communication device 6, so as to avoid the infusion 4 and the second compartment contained in the first compartment 2 Infusion 5 contained in 3 is mixed. In addition, the container is provided with an opening 8 for the infusion 4 to be injected into the first compartment 2, an opening 9 for the infusion 5 to be injected into the second compartment 3, and an opening 10 for the injection of the mixed preparation. If necessary, other chemical agents can be mixed through these openings. Such a container filled with infusion is obtained in the following manner. First, the communication member 6 of the container 1 is closed by a partition member (fastening bolt 7 in this example), and the first and second compartments 2 and 3 are separated from each other, and then the infusion containing fat emulsion and sugar is passed through the opening 8 Inject into the first compartment 2 and inject another solution containing amino acids and electrolytes into the second compartment 3 through the opening 9. In this case, it is better to inject the infusions 4 and 5 into the first and second compartments 2 and 3 under inert gas, such as nitrogen, argon, etc. When the infusions 4 and 5 are filled into the first and second compartments 2 and 3, the openings 8 and 9 are sealed, and the resulting container is sterilized to obtain the container with the infusion sealed in Figure 1. Sterilization can be carried out by any conventional means, for example, by heat sterilization means, such as high-pressure steam sterilization, heat permanent immersion sterilization, hot water spray sterilization, etc. When plastic containers are used in these situations, it is better to sterilize them in a substantially oxygen-free atmosphere. (Please read the precautions before filling in this page) This paper uses the 5Jc standard and uses a Η family standard (CNS) 4 specifications (210x297 public) 81. 4.] 0,000 sheets (Η) Ministry of Economic Affairs Quasi-authorized shellfish consumer cooperation Du Yin 51 320563 Λ_Π6_ V. Description of the invention α2) The thus obtained infusion sealed container of the present invention can be stored as such. Infusion preparations containing fat emulsions, sugars, amino acids, and electrolytes can be used by removing the clasp 7 to make the first and second compartments 2 and 3 communicate with each other, and make each compartment The sealed infusions 4 and 5 are mixed and aseptically mixed. Subsequently, the infusion preparation thus mixed is ejected from the opening 10 in a sterile manner, and administered to a living body through a tube (not shown). Fig. 2 is a cross-sectional view showing another example of the container filled with infusion of the present invention. In this figure, a rectangular container 11 made of plastic material and other materials has two compartments, namely a first compartment 12 and a second compartment 13, which are separated from each other by a large bolt 16. An infusion 14 containing a fat emulsion and sugar is enclosed in the first compartment 12, and another infusion 15 containing amino acids and electrolytes is enclosed in the second compartment 13. Since the first and second compartments 12 and 13 are separated from each other by bolts 16, the infusion 14 in the first compartment 12 and the infusion 15 enclosed in the second compartment 13 are not mixed . In addition, the container 11 is provided with an opening 17 for infusion 14 into the first compartment 12, an opening 18 for infusion 15 into the second compartment 13, and an opening 19 for injection of the mixed preparation . If necessary, other chemicals can be mixed through these openings. The method and usage of the container filled with infusion shown in Figure 2 is basically the same as the container shown in Figure 1. The mixed image of infusion 14, 15 is completed by unscrewing the bolt 16. The container sealed with infusion shown in Figures 1 and 2 is only one subject of the present invention and should not be considered as limiting the scope of the present invention. The shape, size, etc. of the container can be freely changed, as is the partition member. For example, in Figure 1, a clip can be used instead of the fastening bolt 7, or the first and second compartments 2 and 3 can be separated from each other by installing a ball bolt in the communication member 6. $ Can use hot-melt film or (please read the precautions before filling this page) This paper is used in the national standard (CNS) f 4 specifications (210X297 male dragon) 81. 4_ 10,000 sheets (H ) x. '»MJu \ Λ fi 1? 6 Printed by the Ministry of Economic Affairs of the Central Ministry of Industry and Consumers' Association V. Description of the invention (13) Splittable connector. . In the aforementioned process, the infusion containing fat emulsion and sugar to be sealed in the first compartment can be prepared by various methods. For example, sugar can be added to the fat emulsion prepared in advance by the aforementioned procedure, or to the fat / emulsion mixture to be emulsified. Preferably, during the preparation of the fat emulsion, 瑭 is added to the fat so that the average particle size of the fat emulsion becomes 0.17 w m or less. This fat emulsion can be prepared as described above. The composition of the infusion solution containing fat emulsion and sugar can be based on the concentration of the infusion solution to be sealed in the second compartment (in other words, the infusion solution containing amine group p and electrolytes) Any change fee such as volume ratio. The composition-preferred examples include a greaseproof content from 0.1 to 30 :, preferably from 1 to 201, more preferably from 2 to 10¾, and an emulsifier content from 0.01 to 10¾, preferably from 0.05 to 53 :, More preferably from 0.1 to 1%, reducing sugar content: from 5 to 60S :, preferably from 7 to 404, more preferably from 10 to 3.031, and the most suitable water. The infusion solution containing amino acids and electrolytes to be sealed in the second compartment meat can be prepared by various means. For example, each amino acid and electrolyte to be blended can be dissolved in pure water, such as distilled water for injection. The composition of infusions containing group-based acids and decomposables can be injected into the first and second compartments according to the degree of infusion to be sealed in the first compartment (also 6P infusion containing fat emulsion and sugar) The infusion ratio of 縹 縹 is arbitrarily changed. One of the preferred examples of the composition includes the total amount of amino acids from 1 to 15¾. Preferably from 2 to 13¾, more preferably from 3 to 12Λ; and the electrolyte is 50 to 180nEq / il sodium, 40 to 135inEq / Jl potassium, 10 Up to 50 'nEs / calcium calcium, 5 to 30oiEq / magnesium magnesium, 0 to 225nEq / clinic chloride, 3 to 40nEq / clinic phosphorus and 0 to 100 jwmol / zinc, in addition to suitable water. 、 The preferred composition is as follows: / 1¾ Please note 3R -Pl · Fill in · This / page installed η line paper paper size ϋ used in the SS home standard (CNS) T4 regulations «S (210x297 gong) sound Zheng 11 81 -4.] 0,000 ft (B) Λ 6 Π 6 Produced by Beigong Consumer Cooperation of the Bureau of Standards, Ministry of Economic Affairs. Printed by D. V. Description of Invention (14) Electrolytes-Sodium 50 -180 m E q / iL Potassium 40 -135 m E q / Calcium 10 -50 nj E q / Sense m 5 -30 Π! E q / JL Nitrogen 0 -225 rn E q / A_ Phosphorus 3 -4 0 ID E q / Sense zinc 0 -100 household mol / Sense Amino acids L-isoleucine 1-15 g / iL L-leucine 1-20 g / children L-valine 1-15 g / il L-isoamine hydrochloride 1-20 g / il L · -Methionine 0. 5-10 g / Jl L-Phenylalanine 1-15 g / il- L-Phenylalanine 1-15 g / il L-tryptophan 0 • 3-3 g / il L-arginine 1-20 g / sense group |. One Y ·! Amino acid 0.5-10 g / il l · ϋ Gan U ·. Amino acid 0.5-10 g / A. Alanine 1-15 g / iL L-proline acid 0 • 5-15 g / JL L-aspartic acid 0.1-5 g / il L _ serine acid 0.5-10 g / il

(請先閲讀背而之注意事項#填窩本頁) 本紙張尺度逍用中圉國家楳準(CNS)>F4規格(210x297公;«:) 81. 4. 10,000張'(H) 經济部屮央標準局A工消价合作社印製 五、發明説明as) L - 酪 胺 酸 0 . 1 - 1 δ /儿 L - 麩 胺 酸 0 . 1 - 5 g /义 L - 半 胱 胺 酸 0 . 1 - 3 g /儿 本 發 明 之 輸 液 製 劑 之 pH值 鑑 於 對 活 體 安 全 度 之 觀 點 » 可 調 整 至 由 5 . 0至8 .0 t 較 好 由 5 . 5至 7 .5 〇 特 別 y 當 使 用 多 羥 基 醇 或 糖 之 磷 酸 酯 或 酯 m 作 來 源 時 1 即 使 於 相 當 高 之 pH值 下 也 可 有 效 避 免 生 成 沈 澱 〇 各 種 酸 性 物 質 t 較 好 有 機 酸 t 只 要 為 生 理 可 接 受 者 t 皆 可 用 作 輸 液 製 劑 之 pH 調 整 劑 〇 pH 調 整 劑 之 例 包 含 選 白 檸 樣 酸 9 葡 萄 糖 酸 t 乳 酸 > 蘋 果 酸 順 丁 烯 二 酸 及 丙 二 酸 中 之 至 少 種 有 機 酸 〇 此 等 有 機 酸 類 中 j 氧 羧 酸 類 也 可 以 内 酯 或 内 交 酯 之 形 式 使 用 〇 同' ‘時 > 此 等 有 機 酸 類 可 以 其 鹽 形 式 或 與 其 鹽 之 混 合 物 形 式 使 用 0 此 等 有 機 酸 類 之 鹽 包 含 無 機 鹼鹽(如鹼金屬鹽如鈉鹽,鉀鹽等)及有機鹸鹽(如乙醇胺 鹽,N -甲基《萄糖胺鹽,胺基酸鹽等)。此等有機酸類可 使得脂肪乳液對二價金屬離子呈安定。如此,當於此等有 機酸類存在下,將脂肪乳液與含二價金屬離子之溶液温合 時,所得脂肪乳液相當安定,而可避免脂肪粒子之凝集。 可進行二價金屬離子螯合作用之有機酸類為佳,以檸檬酸 為特佳。 可隨時進行pH調整劑之添加。然而,較好,將預定量之 pH調整劑事先加入任一種或兩種輸液,例如糖輸液内。舉 例言之,以第1圖之容器為例,pH調整劑可加入第一及第 二隔間内輸液之一者或二者中。 本紙張尺度边用中困困家標準(CNS)甲4規格(210X297公:《:) 81. 4. 10,000張(H) (請先閲讀背而之注意事項孙填寫本頁) 裝· 訂_ 線_ Λ 6 Π 6 經濟部屮央橾準局A工消价合作杜印製 五、發明説明(16) 欲求避免於滅菌時及儲存期間著色,可將抗著色劑,如 硫甘油,二硫赤絲醇等加入本發明之輸液製劑内,通常其 添加量為約1 %或以下。抗著色劑之添加可隨時進行,然而 ,較好,將預定量之抗著色劑事先加入一種或兩種輸液, 如糖輸液内。舉例言之,以第1圖之容器為例,抗著色劑 可事先加入第一及第二隔間内之一種或兩種輸液内。 此外,本發明之輸液製劑又可與維生素類,如維生素A ,維生素B群,維生素C,維生素D群,維生素E及雒生素K 群等混合。同時,有待封於第一隔間内之輸液可與缓衝劑 ,如L -組胺酸,參(羥甲基)胺基甲烷,等,以0.001至1.0 % ,較好由0 . 0 0 2至0 · 5 % ,更好由0 . 0 0 5至0 · 3 S:之數量混合 。L-組胺酸及參(羥甲基)胺基甲烷可單獨使用或合併使用 ,若有所需,呈鹽類形式使用。酸加成鹽類,如鹽酸鹽等 可用作鹽類。以組胺酸為例,也可使用金屬鹽類,如銷鹽 ,鉀鹽等。此等緩衝劑可於輸液製劑之滅菌與保藏期間, 防止pH值下降及游離脂肪酸産生。如此所得輸液製劑為安 定,及游離脂肪酸濃度降低。 欲求避免封裝後之各組分變性,依本發明之填充以輸液 之容器可包裹以不透氣膜材。此等不透氣膜材之例包含: 三層叠層膜,其中乙烯-乙烯醇共聚物膜,聚乙烯醇膜, 聚偏氯乙烯膜等用作内層(例如,叠層膜包括聚酯膜,拉 張尼龍膜,拉張聚丙烯膜等所製成之外層,及未拉張聚丙 烯膜所製成之内層);具有鋁層之簦層膜(例如,一鋁層置 於聚酯膜與未拉張聚丙烯膜間之一 f膜);及具有無機 (請先閲讀背而之注意事項#蜞寫本頁) 裝· 訂- 線. ^•紙张尺度逍用中Η困家標準(CNS) 規格(2】0x297公货) 81_ 4. 10,000張(1〇 320563 Λ 6 Β 6 經濟部屮央標準局貝工消费合作杜印製 五、 發明説明(17) 材 沈 積 膜 之 壘 層 膜 (例贫 】, 具有矽沈積膜置於聚酯膜與未 拉 張 聚 丙 烯 膜 間 之 一 壘 層 膜 1 具 有 矽 沈 積 膜 置 η 拉 張 尼 龍 膜 與 未 拉 張 聚 丙 烯 膜 間 之 昼 層 膜 具 有 鋁 沈 積 膜 置 於 聚 酷 膜 與 未 拉 張 聚 丙 烯 膜 間 之 簦 層 膜 , 及 具 有 聚 偏 氛 乙 烯 膜 置 於 氣 化 鋁 沈 積 聚 酯 膜 與 未 拉 張 聚 丙 烯 膜 間 之 一 叠 層 膜 )〇 氣 清 除 劑 如 A g el e s S (商 品 名 )可置左 >包裹材與容器間, 或 者 包 裹 以 膜 材 之 容 器 可 以 常 方 式 進 行 真 空 包 裝 > 或 饋 入 惰 性 氣 體 (例如為氮)包 裝 〇 如 此 所 得 之 含 脂 肪 乳 液 Λ 糖 胺 基 酸 類 t 及 電 解 質 類 之 輸 液 製 劑 具 有 卓 越 儲 存 期 » 不 會 發 生 沈 澱 \ 變 性 著 色 等 1 可 儲 一 週 左 右 y 輸 液 製 劑 可 就 此 或 以 純 水 稀 釋 後 * 若 有 所 需 i 緒 由 與 其 他 藥 物 等 混 合 之 後 ) 經 靜 脈 注 射 投 予 病 人 0 也 可 經 由 其 他 投 藥 途 徑 例 如 經 □ 或 經 直 腸 投 藥 等 使 用。 包 括 糖 胺 基 酸 類 -V m 解 質 類 及 脂 肪 乳 液 之 本 發 明 輸 液 製 劑 即 使 於 此 等 組 分 同 時 存 在 時 也 不 會 導 致 生 成 沈 澱 、 相 分 離 變 性 ·> 著 色 等 〇 如 此 ♦ 本 發 明 可 提 供 一 種 具 有 卓 越 . 安 定 度 及 安 全 度 之 輸 液 製 劑 0 此 外 > 依 本 發 明 之 填 充 以 输 液 之 容 器 < 將 含 脂 肪 乳 液 及 糖 之 一 輸 液 t 及 含 胺 基 酸 類 及 電 解 質 類 之 另 一 輸 液 > 分 別 事 先 分 裝 於 彼 此 隔 開 之 二 隔 間 内 t 本 發 明 之 輸 液 製 劑 可 藉 由 ασ 单 純 移 開 附 著 於 容 器 上 之 分 隔 構 件 > 及 於 使 用 時 將 兩 種 •fmr Μ 菌 封 裝 之 液 體 温 合 而 得 〇 換 言 之 t 藉 由 使 用 本 發 明 之 容 器 可 簡 C3C> 单 容 易 地 獲 得 輸 液 製 劑 而 未 於 混 合 時 造 成 微 生 物 污 染 1 歸 因 於 此 製 劑 ^mr m 需 處 理 將 各 別 製 得 的 脂 肪 乳 液 糖 溶 液 胺 基 酸 溶 液 $ 及 電 解 質 裝· 訂- 線. (請先閲讀背而之注意事項#填寫本頁) 本紙張尺度遑用中國國家樣準(CNS) ΤΜ規格(210x297公;«:) 81. 4. 10,000¾ (Η) Λ 6 Ιί 6 經濟部屮央標準局tcx工消仲合作杜印31 五、發明説明(18) 溶液混合的步驟。 下列實施例偽供進一步示例説明本發明之用,而絶不得 視為囿限本發明之範圍。 實施例1 使用混合機將由60g大豆油,7.2g卵黃磷脂,及適量注 射用蒸餾水所組成之混合物攪拌在一起。總體積以注射用 蒸餾水調整為1 0 0 0 π免而得粗乳液。隨後,所得乳液使用 曼頓-高林均化機(15M-8TA,高林公司製造)乳化。500πιΑ_ 整分之如此所得之乳液與2 5 0 g葡萄糖混合,且以注射用蒸 餾水將總體積調整為1000niil。隨後,將所生成之乳液之 P Η調整至6而得輸液製劑。如此所得輸液製劑之組成示於 表1。 50»义容積之玻璃容器内饋入輸液製劑,容器内之空氣 以氮氣置換。隨後,密封填充以輸液製劑之容器及經由以 115Ό高壓蒸氣滅菌30分鐘。滅菌前及後,輸液製劑之外 觀、pH值,及平均粒徑示於表2。J _L_J|_ 大豆油 卵黃磷脂 葡萄糖 注射用蒸餾水 數 量U)303.6250需要量而將總體積 調整為1 0 0 0 m义(Please read the back of the note #fill this page first) This paper standard is used in the Chinese National Standard (CNS) > F4 specification (210x297; «:) 81. 4. 10,000 sheets' (H) Economy Printed by the Ministry of Standards, Bureau A, Affordable Price Cooperative V. Description of the invention as) L) Tyrosine 0.1-1 δ / Child L-Glutamic acid 0.1-5 g / Sense L-cysteine 0.1-3 g / pH of the infusion preparation of the present invention can be adjusted from 5.0 to 8.0 t, preferably from 5.5 to 7.5 in view of the viewpoint of the safety of living body. When using phosphate or ester m of polyhydric alcohol or sugar as the source 1 Even at a relatively high pH value, it can effectively avoid the formation of precipitates. Various acidic substances t Better organic acids t As long as they are physiologically acceptable t The pH adjuster used as an infusion preparation. Examples of the pH adjuster include citric acid 9 gluconate t lactic acid > malate maleic acid and malonic acid. At least one kind of organic acids. Among these organic acids, oxycarboxylic acids can also be used in the form of lactones or lactides. When the same is used, these organic acids can be used in the form of a salt or a mixture of salts thereof. Such organic acid salts include inorganic alkali salts (such as alkali metal salts such as sodium salt, potassium salt, etc.) and organic halide salts (such as ethanolamine salt, N-methylglucosamine salt, amino acid salt, etc.). These organic acids can stabilize fat emulsions to divalent metal ions. In this way, when the fat emulsion and the solution containing divalent metal ions are warmed in the presence of these organic acids, the resulting fat emulsion is quite stable, and the aggregation of fat particles can be avoided. Organic acids that can chelate with divalent metal ions are preferred, with citric acid being particularly preferred. The pH adjuster can be added at any time. However, preferably, a predetermined amount of pH adjusting agent is added in advance to either or both infusions, such as sugar infusions. For example, taking the container in Figure 1 as an example, the pH adjusting agent may be added to one or both of the infusions in the first and second compartments. The size of this paper is used in the middle-sleepy home standard (CNS) A 4 specifications (210X297 public: ":) 81. 4. 10,000 sheets (H) (please read the precautions Sun fills in this page first)线 _ Λ 6 Π 6 The Ministry of Economic Affairs, the Central Bureau of Economics and Trade, the A-Commerce Co-production, Du Printed V. Description of the Invention (16) To avoid coloring during sterilization and storage, anti-coloring agents such as thioglycerol, disulfide Erythritol and the like are added to the infusion preparation of the present invention, and the addition amount is usually about 1% or less. The addition of the anti-coloring agent can be carried out at any time, however, it is preferable to add a predetermined amount of the anti-coloring agent to one or two infusions in advance, such as sugar infusion. For example, taking the container in Figure 1 as an example, the anti-colorant can be added to one or both infusions in the first and second compartments in advance. In addition, the infusion preparation of the present invention can be mixed with vitamins, such as vitamin A, vitamin B group, vitamin C, vitamin D group, vitamin E, and K-group. At the same time, the infusion to be sealed in the first compartment can be combined with buffering agents, such as L-histidine, ginseng (hydroxymethyl) aminomethane, etc., to 0.001 to 1.0%, preferably from 0.0 2 to 0.5%, preferably from 0.005 to 0.3 S: the quantity is mixed. L-histidine acid and ginseng (hydroxymethyl) aminomethane can be used alone or in combination. If necessary, they can be used in the form of salts. Acid addition salts such as hydrochloride can be used as salts. Taking histidine as an example, metal salts, such as potassium salts and potassium salts, can also be used. These buffers can prevent pH drop and free fatty acid production during sterilization and storage of infusion preparations. The infusion preparation thus obtained is stable, and the concentration of free fatty acids is reduced. To avoid denaturation of the components after encapsulation, the container filled with infusion according to the present invention may be wrapped with a gas-impermeable membrane. Examples of such air-impermeable membrane materials include: Three-layer laminated film in which ethylene-vinyl alcohol copolymer film, polyvinyl alcohol film, polyvinylidene chloride film, etc. are used as the inner layer (for example, the laminated film includes a polyester film, a Nylon film, stretched polypropylene film, etc. made of outer layer, and unstretched polypropylene film made of inner layer); film with aluminum layer (for example, an aluminum layer placed on polyester film and One of the f membranes between the stretched polypropylene membranes); and inorganic (please read the back and forth precautions # 蜞 写 this page) Binding · Order-line. ^ • Paper scales for the use of Η sleeper standard (CNS ) Specifications (2) 0x297 public goods) 81_ 4. 10,000 sheets (10320563 Λ 6 Β 6 Beigong Bureau of Economics, Ministry of Economic Affairs, Beigong Consumer Co., Ltd. Du Printing V. Description of the invention (17) Barrier layer of deposited film Membrane (e.g. poor), with a silicon deposited film placed between the polyester film and the unstretched polypropylene film, a barrier film 1 with a silicon deposited film placed η between the stretched nylon film and the unstretched polypropylene film The film has an aluminum deposition film placed on poly-cool film and untensioned poly The interlayer film between the propylene film and the laminated film with the polyvinylidene fluoride film placed between the vaporized aluminum deposited polyester film and the unstretched polypropylene film). Gas scavengers such as A g el es S (commodity Name) Can be placed on the left> Between the packaging material and the container, or the container wrapped with a film material can be vacuum-packed in the usual way> Or fed in an inert gas (such as nitrogen) for packaging. The fat-containing emulsion thus obtained Λ sugar amine group The infusion preparations of acid t and electrolytes have an excellent storage period »No precipitation will occur \ Denatured coloring, etc. 1 Can be stored for about a week y Infusion preparations can be used for this or after dilution with pure water * If necessary, mix with other drugs etc. Afterwards) Intravenous administration to patient 0 can also be used via other routes of administration such as via or rectal administration. The infusion preparation of the present invention including glycosamino acids-V m disintegrations and fat emulsions will not cause precipitation, phase separation and denaturation even when these components are present at the same time. An infusion preparation with excellent stability and safety. 0 In addition> The container filled with infusion according to the present invention < Infusion of one of fat emulsion and sugar t and another infusion containing amino acids and electrolytes> ; Separately pre-packed in two compartments separated from each other t The infusion preparation of the present invention can simply remove the partition member attached to the container by ασ > and encapsulate two types of fmr Μ bacteria during use The liquid is warm to get. In other words, t can be obtained simply by using the container of the present invention C3C > The infusion preparation can be easily obtained without causing microbial contamination during mixing 1 Attributed to this preparation ^ mr m Need to deal with separately prepared fat emulsion sugar solution amino acid solution $ and electrolyte installation · order-line. (Please read the back of the precautions # fill out this page) This paper standard uses the Chinese National Standard (CNS ) ΤΜ specification (210x297 g; «:) 81. 4. 10,000¾ (Η) Λ 6 Ιί 6 tcx Gongxiaozhong Duin 31 of the Central Standards Bureau of the Ministry of Economic Affairs. V. Invention Instructions (18) The steps of solution mixing. The following examples are provided for the purpose of further illustrating the present invention and should not be construed as limiting the scope of the present invention. Example 1 A mixture composed of 60 g of soybean oil, 7.2 g of egg yolk phospholipid, and an appropriate amount of distilled water for injection was stirred together using a mixer. The total volume is adjusted to 100 π with distilled water for injection to avoid coarse emulsion. Subsequently, the resulting emulsion was emulsified using a Manton-Gorlin homogenizer (15M-8TA, manufactured by Gorlin). 500πιΑ_ aliquots of the emulsion thus obtained were mixed with 250 g of glucose, and the total volume was adjusted to 1000 niil with distilled water for injection. Subsequently, the pH of the resulting emulsion was adjusted to 6 to obtain an infusion preparation. The composition of the infusion preparation thus obtained is shown in Table 1. Infusion preparations are fed into a glass container with a 50 ”volume, and the air in the container is replaced with nitrogen. Subsequently, the container filled with the infusion preparation was sealed and sterilized by high-pressure steam at 115 ° for 30 minutes. Table 2 shows the appearance, pH value, and average particle size of the infusion preparation before and after sterilization. J _L_J | _ soybean oil, yolk phospholipid, glucose, distilled water for injection, quantity U) 303.6250, and the total volume is adjusted to 1 0 0 0 m.

本紙張尺度逍用中國困家標準(CNS)甲4規格(2Κ1χ2ί)7公釐) 81. 4. 10,000張(R) (諳先閲讀背而之注意事項再项窍本頁) 五、發明説明(19) 直 試驗項目 滅菌前 白色均質乳液 5.60 0.22^ π Λ 6 Π 6 滅菌後 白色均質乳液 5.03 0 . 2 2 u m 夕卜 觀 pH 平均粒徑 如表2所示 菌後略降。 實施例2 以類似實施例1程序之方式獲得下表3所示之輸液製劑, 但使用果糖置換葡萄糖,並以如例1之相同方式藉高壓蒸 氣滅_。輸液製劑於滅薗後仍可雒持良好狀態的乳液。 表_3_ 量(g) 輸液製劑可維持安定乳液,唯其p Η值於滅 J|_ 大豆油 卵黃磷脂 果糖 注射用蒸餾水 數 30 250 需要量而將總體積 調整為1 0 00 niil (請先閲讀背而之注意事項#填寫本頁) 經濟4屮央標準局貝工消奸合作社印製 實施例 含大豆油及卵黃磷脂之分散条統與甘油或糖(葡萄糖, 山梨糖醇,木糖醇或果糖)混合而得粗乳液。粗乳液於 550kg/ciif之壓力及70¾或以下之溫度,使用曼頓高林均 化機(1 5 Μ - 8 T A,高林公司製造)進一步乳化而得脂肪乳液 ,其組成示於表4。 本紙張尺度返用中國囷家«準(CNS)甲4規格(210x297公龙) 獅、您各 81. 4. 10,000张⑻ 修補充 Λ 6 Π 6 五、發明説明(20) 乳化步驟期間,檢查乳液之平均粒徑之週期性變化。 欲測量平均粒徑,將1 0 0 nil水加入各0 . 1 υ文乳液樣品内作 樣品溶液,及使用M a 1 v e r η自動測徑儀2 C ( M a 1 v e r η公司裂 造)測量樣品溶液之平均粒徑。至於對照係重複相同程序 ,但甘油或各種糖偽以等量水置換。1 結果示於第3圖,其中符號參代表甘油,♦代表葡萄糖 ,〇代表山梨耱醇,□代表木糖醇,▼代表果糖,及▲代 表對照。 _ 4 組 分 (請先閲請背而之注意事項洱填筠本頁) 裝- 大豆油 30 經济部屮夬搮準而员工消坨合作杜印鼓 卵黃磷脂 3.6 甘油或糖 500 注射用蒸餾水 ’需要置而將總體積 調整為1 0 0 0ιπ文 如脑3所示,於對照条統(不含甘油及糖之糸統)中,即 令反麥通過乳.化器3 0次後平均粒徑仍約為0 . 2 /X m。同時, 即令反覆通過乳化器30次後,含山梨瑭醇,木瑭醇及果糖 之条统之平均粒徑仍為0 . 1 S至0 . 2 /X u。相反地,於含甘油 及菊萄糖之条統之例中,隨著反覆通過乳化器,平均粒徑 快速下降。如此,含甘油之条統重複約8次後及含葡萄耱 之条统重複約20次後,平均粒徑達0.17wni。結果顯示甘 油及葡萄糖具有缩小乳液粒徑之高度能力。 ^ 賓施例4 ^ 訂 線_ MUfc尺度边用t a S家搞準(CNS) Ή規格(210x297公¢) 81. 4. 10,000張(H) 320563 A 6 15 6 五、發明説明(21) 經由將60g大豆油,7.2g卵黃磷脂及500g葡萄糖加入水 中製得粗乳液。以水將總體積調整為1 0 0 0 m JL。如此所得 粗乳液使用曼頓-高林均化機(1 5 Μ - 8 T A ,高林公司製造)進 行乳化,直到粒徑逹0 , 1 5 μ m或以下為止,製妥脂肪乳液 。5 0 0 in义整分之如此所得之脂肪乳液與5 0 0 u义水混合。如 此所製妥之脂肪乳液之組成示於表5。容積50rail之玻璃容 器内饋入此製劑及容器内空氣以氮氣置換,繼而密封。隨 後,如此密封後之填充以脂肪乳液製劑之容器經由於11 5 高壓蒸氣滅菌30分鐘。滅菌前及後,製劑之外觀、pH值 ,及平均粒徑經比較,結果示於表6。 • _5_ 量(g) ϋ_ 大豆油 卵黃磷脂 葡萄糖 注射用蒸餾水 數 30 250 需要量而將總體積 調整為1 0 0 0 mil (請先閲請背而之注意事項再填寫本頁) 裝- 訂 線. 經濟部中央標準局货工消费合作社印製 表 試驗項目 滅菌後 外 觀 白色均質乳液 白色均質乳液 pH 5.60 5.01 平均粒徑 0.14Wm 0.14^ m 如表6所示,滅菌後,製劑之乳液條件安定,但P Η值略 降 ^紙張尺度逍用中函Η家標準(CNS) 規格(210x297公;«:) 81. 4. 10,000張(Η) 320563 Λ 6η 6 經濟部屮央櫺半局κχ工消讣合作杜印製 五、發明説明(22) 賁施例5 將42.9niil70%葡萄糖液(70C)加入由42.64g大豆油及 6. 14g卵黃磷脂所組成之混合物(701)後,所得混合物之 總體積以水調整為5 0 0 in义而製妥粗乳液。如此所得之粗乳 液於550kg/CBf之壓力及70它或以下之溫度,使用曼頓高 林均彳t機(15M-8TA,高林公司製造)進行乳化,而得平均 粒徑為0 . 1 7 w ra或以下之脂肪乳液。 賁施例6 1 50〇>义整分之實施例5所得之脂肪乳液與注射用蒸諧水 混合而將總積體調整為5 00iniL。50πι儿容積之玻璃容器内 饋入此製劑,及容器内空氣以氮氣置換,繼·以密封。隨 後,·如此經密封之镇充以製劑之容器藉由於高壓蒸 氣滅菌30分鐘。如此所得製劑顯示可經歴長時間維持良好 乳化狀態。 實施例7 2 0 0 m儿整分之實施例5所得之脂肪乳液與3 0 4 m义注射用 蒸餾水及13_2mjl70%®萄糖溶液混合。50IDJI容積之玻璃 容器内饋入此製劑,及容器内空氣以氮氣置換,繼以密 封。隨後,如此經密封之填充以製劑之容器藉由於1 1 5 °C 高壓蒸氣滅菌30分鐘。如此所得製劑顯示可經歴長時間 雒持良好乳化狀態。 '實施例8 由60g大豆油,7.2g卵黃磷脂及適量水所組成之混合物 使用混合機攪拌,總體積以水調整為1000Π!义而得粗乳液The size of this paper is easy to use the Chinese Standard for Sleepy Family (CNS) Grade A 4 (2Κ1χ2ί) 7 mm) 81. 4. 10,000 sheets (R) (know first read the precautions and then know this page) V. Description of the invention (19) Straight test item White homogenous emulsion before sterilization 5.60 0.22 ^ π Λ 6 Π 6 White homogenous emulsion after sterilization 5.03 0.2 2 um The average particle size of Xibuguan pH is slightly lower as shown in Table 2. Example 2 An infusion preparation shown in Table 3 below was obtained in a similar manner to the procedure of Example 1, except that fructose was used to replace glucose, and it was extinguished by high-pressure steam in the same manner as in Example 1. The infusion preparation can still maintain the emulsion in good condition after extinguishment. Table _3_ Amount (g) The infusion preparation can maintain a stable emulsion, but its p Η value is in the extinction J | _ Soybean oil yolk phospholipid fructose Distilled water for injection 30 250 The required amount and the total volume is adjusted to 1 00 niil (please first Read back and pay attention to the matter # fill out this page) Economics 4 The Central Bureau of Standards and Technology Co., Ltd. printed examples of the dispersion of soybean oil and yolk phospholipids containing glycerin or sugar (glucose, sorbitol, xylitol Or fructose) to obtain a coarse emulsion. The crude emulsion was further emulsified at a pressure of 550 kg / ciif and a temperature of 70 ¾ or below using a Manton Gorin homogenizer (15 Μ-8TA, manufactured by Kobayashi) to obtain a fat emulsion. Its composition is shown in Table 4. The paper size is returned to the Chinese standard «Zun (CNS) A 4 specifications (210x297 male dragons) lion, you 81. 4. 10,000 sheets each ⑻ repair supplement Λ 6 Π 6 V. Description of the invention (20) During the emulsification step, check The periodic change of the average particle size of the emulsion. To measure the average particle size, add 100 nil water to each 0.1 μm emulsion sample to make a sample solution, and use Ma 1 ver η automatic caliper 2 C (M a 1 ver η company cracked) to measure The average particle size of the sample solution. As for the control system, the same procedure was repeated, but glycerin or various glycopeptides were replaced with equal amounts of water. 1 The results are shown in Figure 3, where the symbols refer to glycerol, ♦ represents glucose, ○ represents sorbitol, □ represents xylitol, ▼ represents fructose, and ▲ represents control. _ 4 components (please read the notes on the back of this page first) Pack-Soybean oil 30 The Ministry of Economic Affairs is accurate and the employees work together to cooperate with the duin drum egg yolk phospholipid 3.6 glycerin or sugar 500 distilled water for injection ' It needs to be set to adjust the total volume to 1 0 0 0 ιπ, as shown in the brain 3, in the control system (without glycerol and sugar system), the average particle size after passing the wheat through the milk. It is still about 0.2 / X m. At the same time, even after repeatedly passing through the emulsifier 30 times, the average particle size of the system containing sorbitol, xylitol and fructose is still 0.1 S to 0.2 / X u. On the contrary, in the case of the system containing glycerin and inulin, the average particle size decreases rapidly as it repeatedly passes through the emulsifier. In this way, after repeating the system containing glycerin about 8 times and repeating the system containing grapevine about 20 times, the average particle size reached 0.17wni. The results show that glycerin and glucose have a high ability to reduce the particle size of the emulsion. ^ Bin Shi Example 4 ^ Threading _ MUfc standard edge with ta S home accurate (CNS) Ή specifications (210x297 cm) 81. 4. 10,000 sheets (H) 320563 A 6 15 6 V. Description of invention (21) Via Add 60g soybean oil, 7.2g egg yolk phospholipid and 500g glucose to water to prepare a crude emulsion. The total volume is adjusted to 100 mJL with water. The coarse emulsion thus obtained was emulsified using a Manton-Gauline homogenizer (15 M-8 T A, manufactured by Colin) until the particle size reached 0, 15 μm or less to prepare a fat emulsion. The fat emulsion thus obtained was mixed with 5 0 0 in aliquot and mixed with 5 0 0 u aliquot. The composition of the fat emulsion thus prepared is shown in Table 5. The glass container with a volume of 50 rail was fed with the preparation and the air in the container was replaced with nitrogen and then sealed. Subsequently, the container filled with the fat emulsion preparation thus sealed was sterilized by autoclaving at 115 5 for 30 minutes. Before and after sterilization, the appearance, pH, and average particle size of the preparation were compared. The results are shown in Table 6. • _5_ Amount (g) ϋ_ Soybean Oil Yolk Phospholipid Glucose Distilled Water Number 30 250 Needs and adjust the total volume to 1 0 0 0 mil (please read the precautions before filling in this page) Packing-Stranding . The Ministry of Economic Affairs, Central Standards Bureau, Cargo Consumers Cooperative Printed Table Test Project. Appearance of white homogeneous emulsion after sterilization. White homogeneous emulsion pH 5.60 5.01 Average particle size 0.14Wm 0.14 ^ m As shown in Table 6, after sterilization, the emulsion conditions of the preparation are stable. However, the value of P Η is slightly lowered ^ The paper size is easy to use the Chinese letter H standard (CNx) specifications (210x297; Obituary cooperation du printing 5. Description of the invention (22) Ben Example 5 After adding 42.9niil 70% glucose solution (70C) to the mixture (701) composed of 42.64g soybean oil and 6.14g egg yolk phospholipid, the total The volume was adjusted to 500 in with water to prepare a coarse emulsion. The crude emulsion thus obtained was emulsified at a pressure of 550 kg / CBf and a temperature of 70 or below using a Manton Gorin Juntong machine (15M-8TA, manufactured by Kobayashi) to obtain an average particle size of 0.17 w Fat emulsion of ra or below. Ben Example 6 1 50〇 > The fat emulsion obtained in Example 5 of the aliquots was mixed with distilled water for injection to adjust the total volume to 500 inL. This preparation was fed into a glass container with a volume of 50πι, and the air in the container was replaced with nitrogen, followed by sealing. Subsequently, the container filled with the preparation thus sealed was sterilized by autoclaving for 30 minutes. The preparation thus obtained shows that it can maintain a good emulsified state over a long period of time. Example 7 The fat emulsion obtained in Example 5 with a 200 m aliquot was mixed with 304 m distilled water for injection and 13-2mjl70% ® glucose solution. This preparation is fed into a glass container of 50IDJI volume, and the air in the container is replaced with nitrogen, followed by sealing. Subsequently, the sealed container filled with the preparation was sterilized by high-pressure steam at 115 ° C for 30 minutes. The preparation thus obtained shows that it can maintain a good emulsified state over a long period of time. 'Example 8 A mixture consisting of 60 g of soybean oil, 7.2 g of egg yolk phospholipid and an appropriate amount of water was stirred using a mixer, and the total volume was adjusted to 1000 IU with water!

(請先閲讀背而之注意事項#填寫本頁) 本紙乐尺度边用tsa家榀準(CNS)T4規格(210x297公;《:) 81. 4. 10,000張(H) 五、發明説明(23)。隨後,所得粗乳液使用曼頓高林均化機(1 5 Μ - 8 T A ,高 積 與體 液總 乳 , 之 合 得混 所劑 此衝 如缓 分各 整之 义 示 0Π1所 0 7 5表 之 量 定 預 及 造糖 製萄 司葡 'g 公 0 系 5 林 2 匕 /1 乳 行 進 Η ρ 之 液 乳 得 所 後 隨 ο 文 Ε 8 0 0 11 為 整 raw- 水 餾 蒸 用 射 注 以 液此 輸如 入 , 饋後 内隨 器 〇 容封 璃密 玻以 之繼 積 , 容換 1.置 0Π1氣 5氮 ,藉 氣 空 内 器 容 及 至劑 整製 劑 製 液 輸 得 而 氣 保 蒸W0 ^ -J 力 高 I、 受 5 接 η V 於80 由於 0 劑 » 製 器液 容输 之之 劑後 製 _ 液滅 輸此 以如 充 〇 填鐘 的分 封30 密菌 經滅 肪 脂 離 游 及 、 徑 粒 均70 平表 、 於 值示 ΡΗ果 量結 測 。 , 化 時變 \ ίΕ 8 } 4 期 歷週 經之 驗度 試濃 藏酸 (請先閲讀背而之注意事項再填寫本頁) 經濟部屮央標準局貝工消伢合作杜印製 本紙张尺度遑用中a Η家標準(CNS)甲Ί規格(210X297公釐) 81. 4. 10,000張(Η) 320563 A 6 η 6 五、發明説明(24) 里 百 項 驗 試 度 濃 劑 'iJ 缓 品 gy. 樣 時 小 (C 間0° 時8八、、 存S 儲 對照 比較 經濟部中央標準局Κ5工消费合作社印製 本發明 0 12 24 48 Xj — 組胺酸/ 0.01% pH 5.85 5.65 5.49 5.23 HC1 大小(μπι)** 0.22 0.21 0.22 0,22 游離脂肪酸 0.71 0.83 1.08 2.11 (mEq/l) 0.02% PH 5.89 5.81 5.7 3 5.58 大小(μπι)** 0.22 0-21 0.21 0.22 游離脂肪酸 0.83 0.83 1.20 1.71 (mEq/l) 0.05% pH 5.89 5.78 5.68 5.50 大小(μπι)** 0.21 0.21 0.21 0.22 游離脂肪酸 0.83 0.83 1.32 1.88 (mEg/1) Tris/ HC1 1 mM pH ,· 5.68 4.99 4刀5 4:55 大小(μπι)** 0.21 0.21 0.21 0.22 游離脂肪酸‘ 0.71 0.83 1.69 2.50 (mEq/l) 無 PH 5-29 4.68 4.58 4.38 大 小(μιη)*·* 0.20 0.22 0.21 0.22 游離脂肪酸 0.59 0.83 1.81 3.45 (mEq’/l) κη2ρ〇": Κ2ΗΡΟή L mM PH . 5.10 4.77 4.61 4.39 大小(μπι)** 0-22 0.22 0.21 0.21 游離脂肪酸 0.71 0.83 1.93 3.45 (mEq/l) κ2ηρο4/ 1 mM. pH 5.05 4.75 4.60 4.41 citric 大小(μπι)** 0.21 0.22 0.21 0.22 游離脂肪酸 1.08 0.71 1.93 3.75 (請先閲請背而之注意事項再堝寫本頁) (mEq/l) :平均粒徑C卢w ) 本紙张尺度边用中国a家楳準(CNS)甲4規格(210X297公釐) 8】_ 6. K),00£)張⑻ 裝- 訂 線· Λ Λ 6 η 6 五、發明説明(25) 由表7所示結果顯然易見,本發明之製劑具有卓越功效 ,可防止Ρ Η值下降及游離脂肪酸增高,而對照例及比較例 則觀察到Ρ Η值更顯著下降,及游離脂肪酸急遽升高。如此 ,證實本發明之輸液製劑具有顯然卓越的安定性。 實施例9 由60g大豆油,7.2g卵黃磷脂及適量水所組成之混合物 使用混合機攪拌,總體積以水調整為1 0 0 01〇义而得粗乳液 。隨後,所得粗乳液便用曼頓高林均化機U 5 Μ - 8 T A,高林 公司製造)進行乳化。5 0 0 m儿整分如此所得之乳液與2 5 0 g ϋ萄糖,0.2g L -組胺酸及lg硫基甘油混合,總積體以注 射用蒸餾水調整為1000niil。隨後,所得乳液之pH調整至6 而得輸液製劑。所得輸液製劑之組成示於表8。 容積50H1义之玻璃容器内饋入輸液製劑,及容器内空氣 以氮氣置換,繼以密封。隨後,如此密封後之填充以輸液 製劑之容器藉由於115 °C進行高壓蒸氣滅菌30分鐘。隨後 ,測量於滅菌前及滅菌後之外觀、ρ Η值、平均粒徑,及游 離脂肪酸濃度,結果示於表9。 (請先閲讀背而之注意事項再填寫本頁) 裝. 訂_ 經濟切屮央標準局工消许合作社印31(Please read the back and the precautions # fill out this page) The paper music standard uses tsa home standard (CNS) T4 specifications (210x297 ;; :) 81. 4. 10,000 sheets (H) V. Description of invention (23 ). Subsequently, the resulting coarse emulsion was obtained by using a Manton-Gauline homogenizer (1 5 Μ-8 TA, high product and total body fluid milk), and the mixture was mixed as shown in the table below. Measure and predict the sugar-making grapes Portuguese'g public 0 series 5 Lin 2 dagger / 1 milk travel Η ρ of the liquid milk gains afterwards 文 Ε 8 0 0 11 for the whole raw-distillation for injection The liquid is input as it is. After feeding, the internal container is filled with the glass and the glass is sealed. The volume is changed to 1. Set 0Π1 gas and 5 nitrogen. W0 ^ -J Ligao I, received 5 and received η V at 80. Because 0 doses »The device of the liquid volume of the device is prepared _ The liquid is dispensed. This is divided into 30 minutes. Youhe, the diameter and grain are all 70 flat table, and the pH value is measured in the value., Time-varying \ ίΕ 8} 4 periods of weeks of experience test the concentrated acid (please read the precautions before filling in This page) The Ministry of Economic Affairs, Bureau of Standards, Bureau of Industry and Commerce, cooperated with Du Gong to print this paper, and the standard is used in a Η home standard (CNS) A Ί specification 210X297 mm) 81. 4. 10,000 sheets (Η) 320563 A 6 η 6 V. Description of invention (24) Libai test concentration concentrate 'iJ slow product gy. Sample time is small (0 ° C 8 8 between C , Stored, stored, compared, compared, printed by the K5 Workers and Consumers Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs 0 12 24 48 Xj — histidine / 0.01% pH 5.85 5.65 5.49 5.23 HC1 size (μπι) ** 0.22 0.21 0.22 0,22 Free fatty acid 0.71 0.83 1.08 2.11 (mEq / l) 0.02% PH 5.89 5.81 5.7 3 5.58 Size (μπι) ** 0.22 0-21 0.21 0.22 Free fatty acid 0.83 0.83 1.20 1.71 (mEq / l) 0.05% pH 5.89 5.78 5.68 5.50 Size (Μπι) ** 0.21 0.21 0.21 0.22 free fatty acids 0.83 0.83 1.32 1.88 (mEg / 1) Tris / HC1 1 mM pH, 5.68 4.99 4 knives 5 4:55 size (μπι) ** 0.21 0.21 0.21 0.22 free fatty acids' 0.71 0.83 1.69 2.50 (mEq / l) No PH 5-29 4.68 4.58 4.38 Size (μιη) * · * 0.20 0.22 0.21 0.22 Free fatty acid 0.59 0.83 1.81 3.45 (mEq '/ l) κη2ρ〇 ": Κ2ΗΡΟή L mM PH. 5.10 4.77 4.61 4.39 Size (μπι) ** 0-22 0.22 0.21 0.21 Free fatty acid 0.71 0.83 1.93 3.45 (mEq / l) κ2ηρο4 / 1 mM. PH 5.05 4.75 4.60 4.41 citric Size (μπι) ** 0.21 0.22 0.21 0.22 Free fatty acid 1.08 0.71 1.93 3.75 (Please read the notes on the back before writing this page) (mEq / l): average particle size C Lu w) This paper uses the Chinese a Jiaju standard (CNS) A 4 specifications (210X297 mm) 8] _ 6. K), 00 £) Zhang ⑻ Binding-Strapping · Λ Λ 6 η 6 V. Description of the invention (25) The results shown in Table 7 are obviously easy to see, the preparation of the present invention has excellent efficacy and can be prevented The pH value decreased and the free fatty acid increased, while the control and comparative examples observed a more significant decrease in the pH value and a sharp increase in free fatty acid. In this way, it is confirmed that the infusion preparation of the present invention has apparently excellent stability. Example 9 A mixture composed of 60 g of soybean oil, 7.2 g of egg yolk phospholipid, and an appropriate amount of water was stirred using a mixer, and the total volume was adjusted to 100 000 with water to obtain a coarse emulsion. Subsequently, the resulting coarse emulsion was emulsified with a Manton Goolin homogenizer U 5 Μ-8TA (manufactured by Kobayashi). The emulsion thus obtained was aliquoted at 500 m, mixed with 250 g of glucose, 0.2 g of L-histidine and lg thioglycerol, and the total volume was adjusted to 1000 niil with distilled water for injection. Subsequently, the pH of the obtained emulsion was adjusted to 6 to obtain an infusion preparation. The composition of the obtained infusion preparation is shown in Table 8. A glass container with a volume of 50H1 is fed with an infusion preparation, and the air in the container is replaced with nitrogen and then sealed. Subsequently, the container filled with the infusion preparation thus sealed was autoclaved at 115 ° C for 30 minutes. Subsequently, the appearance, pH value, average particle diameter, and free fatty acid concentration before and after sterilization were measured. The results are shown in Table 9. (Please read the precautions before filling in this page) Packing. Order _ Economical and Economic Standards Bureau Bureau of Industry and Consumer Cooperation Cooperative 31

A7 B7 五、發明説明(26 ) 表 分 數 量U) 大豆油 卵黃磷脂 葡萄糖 L -組胺酸 硫代甘油 注射用蒸餾水 30 250 需要量而將縴體積 調整為1 000b & (請先閲讀背面之注^^項再填寫本頁,) 裝· 表 試驗項目 外 觀A7 B7 V. Description of the invention (26) Number of points U) Soybean oil yolk phospholipid glucose L-histidine thioglycerol distilled water for injection 30 250 The amount of fiber required to adjust the fiber volume to 1 000b & (Please read the back Note ^^ item and then fill in this page,) Install · Table test item appearance

pH 平均粒徑 游離脂肪酸濃度 滅菌前 白色均質乳液 5.60 0 . 2 2 w m 0.59mEq/ fi 滅菌後 白色均質乳液 5.03 0 . 2 2 ju π 0 . 71mEq/αpH Average particle size Free fatty acid concentration Before sterilization White homogeneous emulsion 5.60 0.2 2 w m 0.59mEq / fi After sterilization White homogeneous emulsion 5.03 0. 2 2 ju π 0. 71mEq / α

A 經濟部中央橾準局員工消费合作社印製 Μ注射用蒸餾水調整為1 0 0 0 m fl 。 如表9所示,pH值因滅菌而略降及游離脂肪酸濃度增高 少許,但製劑仍維持安定的乳化條件。 實施例10 由60g大豆油,7.2g卵黃磷脂,500g葡萄糖及逋量水所 組成之混合物使用混合機攪拌,總體積Μ水調整為 lOOOnfl而得粗乳液。嫌後,所得粗乳液使用曼頓高林均化 機(15M-8TA,高林公司製造)進行乳化。500·!!整分如此 所得之乳液與0.2g L-組胺酸及lg硫代甘油混合。總體積 ί钱 ΐ#〉、所得乳液之pH調 本紙張尺度逋用中國國家梯隼(CNS ) Λ4规格(210X297公簸) 修成霣 Λ 6 η 6 ^¾部中央榀準局貝工消赀合作社印製 五、發明説明(27) 整至6而得輸液製劑。容積50πι儿之玻璃容器内饋入输液 製劑及容器内空氣以氮氣置換,繼以密封。隨後,如此 密封後之填充以輸液製劑之容器藉由於進行高壓蒸 氣滅菌30分鐘。隨後,測量於滅菌前及滅菌後之外觀, pH值、平均粒徑、及游離脂肪酸濃度,結果示於表10。 ^_18 試驗項目 滅菌前 滅菌後 外 觀 白色均質乳液 白色均質乳液 pH 5.71 5.32 平均粒徑 0.14WB 0 . 1 4 χζ m 游離脂肪酸濃度 0.50niEq /义 Θ. 65a.Eq/iL 如表10所示,pH值因滅菌而略降及游離脂肪酸濃度增高 少許,但製劑仍雒持安定的乳化條件。 實施例11 (A)輸液製劑及安定度試驗: 以類似實施例10之程序之方式,製備封於玻璃容器内之 四種輸液製劑(共有3樣品),其各別組成如表11所示。使 用此等製劑於下述條件下進行安定度試驗。 儲存溫度:4 0它 濕度:75$ 儲存期:0 , 1 , 2及値月。 (請先閲讀背而之注意亊項4填寫本頁} 裝· 線-A Printed by the Employee Consumer Cooperative of the Central Ministry of Economic Affairs of the Ministry of Economy Μ Distilled water for injection is adjusted to 100,000 m fl. As shown in Table 9, the pH decreased slightly due to sterilization and the concentration of free fatty acids increased a little, but the formulation still maintained stable emulsifying conditions. Example 10 A mixture composed of 60 g of soybean oil, 7.2 g of egg yolk phospholipid, 500 g of glucose, and a quantity of water was stirred using a mixer, and the total volume of water was adjusted to 100 Onfl to obtain a crude emulsion. Afterwards, the resulting coarse emulsion was emulsified using a Manton Goolin homogenizer (15M-8TA, manufactured by Kobayashi). 500 · !! Emulsify the emulsion thus obtained with 0.2 g of L-histidine acid and 1 g of thioglycerol. Total volume ί 钱 lb #>, the pH of the obtained emulsion is adjusted to the paper size using the Chinese National Falcon (CNS) Λ4 specification (210X297 turbulence). It is built into a Λ 6 η 6 ^ ¾ Ministry of Central Bureau of Industry and Commerce Beigong Consumer Cooperative Print 5. Description of the invention (27) Adjust to 6 to get the infusion preparation. A glass container with a volume of 50 μm was fed with infusion preparation and the air in the container was replaced with nitrogen and then sealed. Subsequently, the container filled with the infusion preparation thus sealed was sterilized by autoclaving for 30 minutes. Subsequently, the appearance, pH value, average particle size, and free fatty acid concentration before and after sterilization were measured. The results are shown in Table 10. ^ _18 Test items Appearance of white homogeneous emulsion before sterilization after sterilization White homogeneous emulsion pH 5.71 5.32 Average particle size 0.14WB 0. 1 4 χζ m Free fatty acid concentration 0.50niEq / 义 Θ. 65a.Eq / iL As shown in Table 10, pH The value decreased slightly due to sterilization and the concentration of free fatty acids increased a little, but the preparation still maintained stable emulsifying conditions. Example 11 (A) Infusion preparation and stability test: In a similar manner to the procedure of Example 10, four infusion preparations (a total of 3 samples) sealed in glass containers were prepared, and their respective compositions are shown in Table 11. The stability test was conducted under the following conditions using these preparations. Storage temperature: 4 0 It Humidity: 75 $ Storage period: 0, 1, 2 and lunar. (Please read back to note first item 4 fill in this page) 装 · 线-

本紙尺度边用中困國家橒毕(CNS) Ή規格(210x297公;«:) 81. 6. 10,000張(Η) A 6 η 6 五、發明説明(28) 表_i_L_ _i_數 量 U) 大豆油 33 卵黃磷脂 4.8 葡萄糖 250 L -組胺酸 0,0.05, 01 或 0.15 注射用蒸餾水 將總體積調整為1 0 0 0 m义 所需之量 (B)試驗結果: 如下所示,其中脂肪乳液像與還原糖摻混之該種輸液製 劑之安定度可藉添加L-組胺酸而顯著獲得改變。 (1 )外觀 所有受試製劑於整個儲存期間皆顯示白色均勻乳化之外 觀。 (i i ) pH 表1 2顯示於試驗之開始及儲存期間各製劑之P Η值。表中 ,Ρ Η值係以3樣品之平均值表示。 如表12所示,pH值隨L-組胺酸之.濃度成正比地受抑制 (請先閲誚背而之注意事項再蜞舄本頁) 裝· 線_ > 經濟部+央榀準局员工消仲合作社印製The size of this paper is used in the middle-sleepy country (CNS) Ή specification (210x297 g; «:) 81. 6. 10,000 sheets (Η) A 6 η 6 V. Description of invention (28) Table _i_L_ _i_number U) Large Soybean oil 33 Yolk phospholipid 4.8 Glucose 250 L-histidine 0,0.05, 01 or 0.15 Distilled water for injection to adjust the total volume to 1 0 0 0 m the amount required (B) Test results: As shown below, where the fat emulsion The stability of this infusion preparation like blending with reducing sugar can be significantly changed by adding L-histidine. (1) Appearance All tested preparations showed white uniform emulsification throughout the storage period. (i i) pH Table 12 shows the pH value of each formulation at the beginning of the test and during storage. In the table, the Η value is expressed as the average of 3 samples. As shown in Table 12, the pH value is proportional to the concentration of L-histidine. The concentration is inhibited (please read the precautions before reading this page). Installation · Line_ > Ministry of Economic Affairs + Central Government Printed by the Bureau ’s employees

本紙51c尺度边用中函Η家楳準(CNS)甲4規格(210X297公釐) 81. 4. 10,000張\Η) 五、發明説明(29) Λ 6 Π 6 經濟部中央棵準局貝工消炸合作社印製 表 12 L-組 胺酸濃度 pH ⑴ 於40P 之儲存月數 0 時 1 2 3 0 4.33 4.58 4.58 4.46 0 .005 5.19 5.37 5.24 5.11 0 .01 5.64 5.65 5.54 5.43 0 .015 5.80 5.84 5.70 5.58 (i U)平均粒徑 表 1 3顯示於試驗之初始及儲存期間各製劑之平均粒徑。 表中 ,各平均粒 徑(單 位,wm)傺以3樣品之平均值表示。 如 表1 3所示, 整體儲存期間各製劑之平均粒徑幾乎不變。 表 13 L-組 胺酸濃度 平均 粒徑U m) U) 於40Ό 之儲存月數 0 時 1 2 3 0 0.15 0.15 0.16 0.16 0 .005 0.15 0.15 .0.16 0.17 0 .01 0.16 0.16 0.16 0.17 0 .015 0.16 0.15 0.16 0.17 (i ν )游離脂肪酸濃度 _表14顯示於試驗之初始及儲存期間各製劑之游離脂肪酸 濃度。表中,各游離脂肪酸濃度(單位,mEq/儿)傜以3樣 品之平均值表示。 尺度边用中S國家樣苹(CNS) Ή規格(2〗0><297公;《:) 81. 4. 10,000張'(H) (請先閲讀背而之注意事項再蜞寫本頁) 裝· 訂_ 線- 經濟部中央標準局Μ工消赀合作杜印製 五、發明説明(30) 如 表 14所 示 » 游 離 脂 肪 酸濃 度之升高隨L- 組胺酸之濃度 成 比 例 地 受 ’到 抑 制 0 表 14 L - 組 胺 酸 濃 度 游離脂肪酸 濃度UE q/九) ⑴ 於40它之 儲存月數 0 時 1 2 3 0 1 . 62 2 .26 3 .47 3.80 0 .005 0 . 62 0 .91 1 .69 2.16 0 .0 1 0 . 40 0 .77 1 .20 1.64 0 .0 15 0 . 40 0 • 70 0 .99 1.43 實 施 例 12 由 79 .2 g大豆油, 9 .5 g卵黃磷脂及 6 0 0g菊萄糖„所組 成之 U 合 物 以 水 調 整 為 總 體 積 1000 m儿, 所得混合物使用 曼頓 高 林 均 化 機 (15M -8TA t 高 林公 司製造)乳化。 如此所 得乳 液 以 2 . 4倍體積水稀釋及過濾。 50m儿容積玻 璃瓶内饋入如 此 稀 釋 後 之 乳 液 > 瓶 内 空 氣以 氮氣置換,繼 以密封。 隨後 » 如 此 密 封 後 之 填 充 以 稀 乳液 之瓶藉由於1 1 5 °C進行 高壓 蒸 氣 滅 m 30分 鐘 0 如 此 所 得製 劑於後文稱為 ”加糖脂 肪乳 液 ” 0 另 外 > 製 得 含 有 如 表 1 5所示^ 之胺基酸類及 電解質類之溶 液 及 分 成 各 別 整 分 〇 將 0M 80mEq/Jl 檸檬酸加入各溶 液之 分 別 整 分 後 9 所 得 溶 液 經 過濾 〇 5 0 it !义容積之玻璃瓶 内舍員 入 所 生 成 之 濾 液 » 瓶 内 空 氣藉 氮氣置換,繼 以密封。 隨後 ,如此經密封的填充以稀乳液之瓶藉由於1151高壓蒸氣 __ 尺度遑用中國Η家«毕(CNS)T4規格(210X297公没) 81. 4. 10,000張(H) (請先閲ift背而之注意事項再堝窍本頁) 裝- 線· Λ 6 η 6 五、發明説明(31) 滅菌30分鐘。如此所得製劑於後文稱為”胺基酸+電解質 溶液”。如此製妥之溶液各別調整至p Η 6 . 3至6 . 4。 以無菌方式由瓶中取出2®il整分之胺基酸+電解質溶液 並移入15mJl容積之無菌聚苯乙烯管内。其次,以無菌方 式由瓶中取出4id义加糖脂肪乳液並移入聚苯乙烯管内,將 溶液與乳液混合,繼以將管密封。相對於胺基酸+電解質 溶液内之檸樣酸濃度,以一週時間測量如此製妥之混合物 之混濁度,平均粒徑及外觀之變化,結果示於表16。此種 情況下,脂肪乳液之平均粒徑僳藉光繞射法測量,而混濁 度係以於光學管)之吸光率表示。 (請先閲讀背而之注念事項再填寫本頁) 裝· 經濟部屮央櫺準局C3:工消奸合作社印製 IV 平 豕 腿 公 \": 81 ft( °° ο 10 奪 •,:';T·'',. ..':κ' 經夼部中央榀準局员工消费合作社印ai Μ》狀 補充 A 6 Π 6 五、發明説明(32) 分. .電解質 胺基酸 .氣化鈉 氯化鉀 硫酸f美· 7Η20 葡萄耱_酸鈣*η2〇 磷酸甘油酯二鉀 (50%) 乙酸鈉·3Η2〇 硫酸鋅· ·7Η20 L-異白胺酸. L—.白按酸 •L-·纈胺酸 L-離胺酸.HC1 蛋胺酸 苯基丙胺酸 L-酥胺酸 L-色胺酸 L-精胺酸 L-組胺酸_ 表 15 瀵 度 (毎升) 1.949 3.500 2.054 6-352 gg g g 10.688 g 11.340 9.585 '8.000 14.000 g mg gg 8.000 q 10.000 g 4.000 g 8 - 000 q 6.000 g 1.200 g 10.500 g 5.〇〇〇 g 先 閲 in. 背 而 之 t-事 項 裝 玎 線 私柢法尺度迟用taa家橒準(CHS)T4規格(210X297公龙) 擎正象 81. S. 10,000¾ (H) 五、發明説明(33) 表 15 (續) 濃 度 (每升 分 甘 胺 酸 5. 300 g L- 丙 胺 酸 8- .500 g L-:脯 胺 酸 6_ .000 g L- 天 冬 胺酸 1, • 500 g L- .絲 胺 酸 3, .000 g L- 酪 胺 酸 0. • 500 g L- .麩 胺 酸 1 .500 g Ν-乙 m 基-L-半胱胺酸 1 • 100 g 其他成份 注射用蒸餾水 適量 (請先間讀背而之注意事項#填寫本頁) 裝· 訂 線.The 51c scale of this paper is used in the letter of the Chinese letter 揳 楳 quasi (CNS) A 4 specifications (210X297 mm) 81. 4. 10,000 sheets \ Η) Fifth, the description of the invention (29) Λ 6 Π 6 Central Bureau of Economics Ministry of Economic Affairs Printed by the Explosives Cooperative Association 12 L-histidine acid concentration pH ⑴ Storage months at 40P 0 hours 1 2 3 0 4.33 4.58 4.58 4.46 0 .005 5.19 5.37 5.24 5.11 0 .01 5.64 5.65 5.54 5.43 0 .015 5.80 5.84 5.70 5.58 (i U) Average particle size Table 13 shows the average particle size of each formulation during the initial and storage periods of the test. In the table, each average particle size (unit, wm) is expressed as the average of 3 samples. As shown in Table 13, the average particle size of each formulation during the entire storage period is almost unchanged. Table 13 L-histidine concentration average particle size U m) U) Storage month at 40Ό 0 hour 1 2 3 0 0.15 0.15 0.16 0.16 0 .005 0.15 0.15 .0.16 0.17 0 .01 0.16 0.16 0.16 0.17 0 .015 0.16 0.15 0.16 0.17 (i ν) free fatty acid concentration_ Table 14 shows the free fatty acid concentration of each formulation during the initial and storage periods of the test. In the table, each free fatty acid concentration (unit, mEq / child) is expressed as the average of 3 samples. Standard-Side National Sampling (CNS) Ή Specification (2〗 0> < 297 g; ":) 81. 4. 10,000 sheets" (H) (Please read the precautions before writing this page ) Installation · Order _ Line-Printed by the Ministry of Economic Affairs, Central Standards Bureau, Monggong and Co., Ltd. V. Description of the invention (30) As shown in Table 14 »The increase in free fatty acid concentration is proportional to the concentration of L-histidine Suppressed to 0 Table 14 L-histidine concentration free fatty acid concentration UE q / nine) ⑴ At 40 months of its storage at 0 hours 1 2 3 0 1. 62 2 .26 3 .47 3.80 0 .005 0. 62 0 .91 1 .69 2.16 0 .0 1 0. 40 0 .77 1 .20 1.64 0 .0 15 0. 40 0 • 70 0 .99 1.43 Example 12 made from 79.2 g soybean oil, 9.5 The U compound composed of g egg yolk phospholipid and 600 g of inulin was adjusted to a total volume of 1000 m with water, and the resulting mixture was emulsified using a Manton Gorin homogenizer (manufactured by Kobayashi 15M-8TA t). The emulsion thus obtained Dilute and filter with 2.4 volumes of water The 50m volume glass bottle is fed with such diluted emulsion > The air in the bottle is replaced with nitrogen and then sealed. Then »The bottle filled with dilute emulsion after such sealing is extinguished by high pressure steam at 115 ° C m 30 minutes 0 The preparation thus obtained is hereinafter referred to as "sweetened fat emulsion" 0 In addition > A solution containing amino acids and electrolytes as shown in Table 15 is prepared and divided into aliquots. 0M 80mEq / Jl Citric acid was added to each solution and aliquoted separately. The resulting solution was filtered. The resulting filtrate was filtered into a glass bottle with a defined volume »The resulting filtrate» The air in the bottle was replaced with nitrogen and then sealed. Sealed bottle filled with dilute emulsion due to 1151 high-pressure steam __ standard using Chinese H home «Bi (CNS) T4 specifications (210X297 public) 81. 4. 10,000 sheets (H) (please read ift first Matters needing attention on this page) Installation-line · Λ 6 η 6 5. Description of the invention (31) Sterilize for 30 minutes. The preparation thus obtained is hereinafter referred to as "amino acid + electrolyte solution". The solutions prepared in this way are adjusted individually to pH 6.3 to 6.4. Take a 2 il aliquot of amino acid + electrolyte solution from the bottle in a sterile manner and transfer it to a sterile polystyrene tube with a volume of 15 mJl. Next, the 4id sugar-added fat emulsion was taken out of the bottle in a sterile manner and transferred into a polystyrene tube, the solution and the emulsion were mixed, and then the tube was sealed. Relative to the citric acid concentration in the amino acid + electrolyte solution, the turbidity, average particle size and appearance of the mixture thus prepared were measured in one week. The results are shown in Table 16. In this case, the average particle size of the fat emulsion is measured by the light diffraction method, and the turbidity is expressed by the absorbance of the optical tube). (Please read the back-to-back notes first and then fill out this page) Outfit · Ministry of Economic Affairs, Pyongyang Bureau C3: Printed by the Workers' Co-operative Society IV Pingyi Legg \ ": 81 ft (°° ο 10 won • ,: '; T' '', .. ': κ' supplementary A 6 Π 6 by the Ministry of Economy, Trade and Industry Central Bureau of Consumer Affairs Cooperative Printing Ai Μ V. Description of invention (32) points. Electrolyte amino acid .Gasification sodium chloride, potassium sulfate, sulfuric acid, 7H20, grapevine acid-calcium * η2〇 diglyceryl phosphate dipotassium (50%) sodium acetate, 3H2Zn sulfate, 7H20 L-isoleucine. L-. White Press acid • L- • Valine L-Iminic acid. HC1 Methionine phenylalanine L-Vulneric acid L-tryptophan L-arginine L-histidine _ Table 15 渵 度 (Each L) 1.949 3.500 2.054 6-352 gg gg 10.688 g 11.340 9.585 '8.000 14.000 g mg gg 8.000 q 10.000 g 4.000 g 8-000 q 6.000 g 1.200 g 10.500 g 5.〇〇〇g first read in. Back to t -Matters related to the use of the private standard method of late use of the taa house standard (CHS) T4 specifications (210X297 male dragons). Engine image 81. S. 10,000¾ (H) 5. Description of the invention (33) Table 15 (continued) Concentration (Glycine 5.300 g L-propylamine per liter 8- .500 g L-: proline 6_ .000 g L-aspartic acid 1, • 500 g L-. Serine 3, .000 g L- tyrosine 0. • 500 g L-. Glutamate 1.500 g Ν- 乙 M 基 -L-cysteine 1 • 100 g other components of the appropriate amount of distilled water for injection (please read the back and the precautions # fill in this page) Packing and threading.

經濟部+央標準局Μ工消费合作杜印M 卜紙张尺度边用中因Η家楳準(CHS)肀4規格(210x297公龙) 祕 81. 6. 10,000張(H) 320563 Λ 6 η 6 五、發明説明(34)Ministry of Economic Affairs + Central Bureau of Standards, M Industry and Consumer Cooperation, Du Yin M, the paper size of the middle use, the family of 揳 楳 quasi (CHS), 4 specifications (210x297 male dragon), 81. 6. 10,000 sheets (H) 320563 Λ 6 η 6 V. Description of the invention (34)

表 16 經下 列時間 後測量: 試驗項目 檸樣酸濃度 0小時 24小時 4 8小時 1 週 .混 濁度. 0 mEq/1 0.034 0.083 0.098 0.097 13 mEq/1 0.033 0.055 0.063 0.080 20 mEq/1 0.033 0.050 0-057 0.069 27 mEq/1 0.034 0.063 0.070 0.085 平 均粒徑 0 mEq/1 0.152 0.187 0.194 0.200 (μη) 13 mEq/1 0,152 0.170 0.173 0.177 20 mEq/1 0.148 0.165 0.174 0.179 27 mEq/1 0.155 0.173 0.180 0.189 外觀θ 0 mEq/1 N C C D 13 mEq/1 N 1 A B D 20 mEq/1 N N A B 2Ί mEq/1 N N A CTable 16 Measured after the following time: Test item Citric acid concentration 0 hours 24 hours 4 8 hours 1 week. Turbidity. 0 mEq / 1 0.034 0.083 0.098 0.097 13 mEq / 1 0.033 0.055 0.063 0.080 20 mEq / 1 0.033 0.050 0 -057 0.069 27 mEq / 1 0.034 0.063 0.070 0.085 Average particle size 0 mEq / 1 0.152 0.187 0.194 0.200 (μη) 13 mEq / 1 0,152 0.170 0.173 0.177 20 mEq / 1 0.148 0.165 0.174 0.179 27 mEq / 1 0.155 0.173 0.180 0.189 Appearance θ 0 mEq / 1 NCCD 13 mEq / 1 N 1 ABD 20 mEq / 1 NNAB 2Ί mEq / 1 NNAC

及 滴 •» —ffl 滴成_ 油形 ·,;成與 結結形結 凝凝與凝化 為>然結幅變 略顯凝大無 f / / / »« A B c DN (請先閱讀背而之注念事項再場寫本頁) 經濟部屮央榀準局β工消设合作社印製 本紙張尺度逍用中8®家樣準(CNS)甲4規格(210X297公*) ^-' 81. 6. 10,000張(H) 經濟部屮央標準局C5T:消费合作社印製 五、發明説明(35) 如表16所示,混濁度及平均粒徑之增高皆受到加入檸樣 酸之抑制,但外觀僅略有改變。 實施例1 3 於氣氣流下,將預定數量之表1 7及表18所不之胺基酸類及 電解質類溶解於維持於8 0它之注射用蒸餾水中,所得溶液 以檸檬酸調整為Ρ Η 6 · 2。過濾溶液後,所得濾液置於氮置 換之玻璃瓶内,藉由於115t高壓蒸氣滅菌30分鐘。使用 如此滅菌後之製劑進行加速保藏試驗。如此,可於滅菌後 即刻及於8 0 T:保藏4 8小時後測量濾液之外觀、著色度,及 P Η值。結果示於表1 9。此例中,著色度係以於4 5 0 n id之吸 光率表示(5 cm光學管)。 (請先閲讀背而之注意事項典填寫本頁) 裝· 6紙张尺度边用中因Η家《毕(CHS) 規格(210x297公龙) 81. 4. 10,000張(Β) 2 320563 Λ 6 Π 6 五、發明説明(36) Μ_11 組 分_ 濃度(每赶..!· 經濟部屮央榀準局Α工消费合作杜印製 L— 異 白 胺 酸. 8.000 g L-. 白 胺 酸 14.000 g L-. 纈 胺 酸 8.000 g L- 離 胺 酸.HC1 10.000 g L- 蛋 胺 酸 4.000 g L- 苯 基 丙 胺酸,. 8.000 g L— 酥 胺 酸 6.000 g L-色 胺 酸 1.200 g L- •精 胺 酸. 10.500 g L— 組 胺 酸 5.000 g 甘 胺 酸 5.300 g L· -丙 胺 酸 8.500 g L- -脯 胺 酸 6.000 g L- -天 冬 胺 酸 1.500 g L- -絲 胺 酸 3.000 g L-酪 胺 酸 0.500 g L· -麩 胺 酸 1.500 g N- -乙 基-L-半胱胺酸 1.100 g (請先間請背而之注悉事項孙塡寫本頁) 本紙張尺度通用中ϋ Η家樣準(CNS)Ή規格(210X297公龙) V 81. 6. 10,000張(Η) 五、發明説明(37) Μ_I! 組. 分_ . .遨 度(每升) 氨 化鈉: 1.949 g 氯 化鉀 3.500 g . 硫 酸鎂 *7H20 2.054 g 葡萄 糖酸鈣*h2o 6'; 352 g 磷酸甘油酯二鉀. (50%) 10.688 g 乙 酸鈉· 3H20 11.340 g 碕酸 鋅 *7H20 9.585 mg m i9 驗項目 恰於滅菌後 .於8 0 C儲存後 4 8小時. 外觀 無色與透明 無色與透明 色度 0-001 C .005 PH 6.23 6 .25 先 閲 背 之, 注· 事 項 斗 S 5And drops • »—ffl drops into _ oil-shaped, ;; formation and knot-shaped knot condensation and condensation into > but the knot width becomes slightly condensed f / / /» «AB c DN (please read first The back-to-back matters will be written on this page.) The Ministry of Economic Affairs, Ministry of Economic Affairs, Central Bureau of Industry and Commerce β-Consumer Cooperative Cooperative Printed This Paper Standard for Small Use 8® Home Sample Standard (CNS) A4 Specification (210X297) * ^- '81. 6. 10,000 sheets (H) Printed by the Consumer Cooperative Standards Bureau C5T: V. Description of invention (35) As shown in Table 16, the increase in turbidity and average particle size is affected by the addition of citric acid Suppressed, but the appearance only changed slightly. Example 13 Under a gas flow, a predetermined amount of amino acids and electrolytes shown in Table 17 and Table 18 were dissolved in distilled water for injection maintained at 80 ° C, and the resulting solution was adjusted to Η with citric acid 6 · 2. After filtering the solution, the resulting filtrate was placed in a nitrogen-replaced glass bottle and sterilized by 115t high-pressure steam for 30 minutes. The preparation after such sterilization is used for an accelerated storage test. In this way, the appearance, coloring degree, and pH value of the filtrate can be measured immediately after sterilization and after storage at 80 T: 48 hours. The results are shown in Table 19. In this example, the degree of coloring is represented by the absorbance at 4 5 0 n id (5 cm optical tube). (Please read the back-end precautions and fill in this page first) Packing · 6 paper scales for the use of the "House (CHS) specifications (210x297 male dragon) 81. 4. 10,000 sheets (B) 2 320563 Λ 6 Π 6 V. Description of the invention (36) Μ_11 component_concentration (Every time .. ·· The Ministry of Economic Affairs, Bureau of Industry and Economics, A-Consumer Co., Ltd., Du-printed L-isoleucine. 8.000 g L-.leucine 14.000 g L-. Valinic acid 8.000 g L-Iminic acid. HC1 10.000 g L-Methionine 4.000 g L-Phenylalanine, 8.000 g L- Phenylalanine 6.000 g L-Tryptophan 1.200 g L- • Arginine. 10.500 g L-histidine 5.000 g glycine 5.300 g L-alanine 8.500 g L-proline 6.000 g L-aspartic acid 1.500 g L-serine Acid 3.000 g L-tyrosine 0.500 g L-glutamic acid 1.500 g N-ethyl-L-cysteine 1.100 g (please note the matter in advance Sun Sun wrote this page) this Paper standard universal ϋ Η home sample standard (CNS) Ή specification (210X297 male dragon) V 81. 6. 10,000 sheets (Η) 5. Description of the invention (37) Μ_I! Group. Points _.. Degree (per liter) Ammoniation Sodium: 1.949 g potassium chloride 3.500 g. Magnesium sulfate * 7H20 2.054 g calcium gluconate * h2o 6 '; 352 g dipotassium glycerol phosphate. (50%) 10.688 g sodium acetate 3H20 11.340 g zinc zincate * 7H20 9.585 mg m i9 test items are just after sterilization. 4 8 hours after storage at 80 C. Appearance colorless and transparent colorless and transparent chromaticity 0-001 C .005 PH 6.23 6 .25 Read the back first, Note · Matter S 5

T 線 經濟部屮央梂準局貝工消费合作社印5i 本紙張尺度逍用中a國家楳準(CNS) Ή規格(210χ2ί)7公龙)\ 修正頁 81. 6. 10,000¾ (Η)T-line 5i printed by the Beigong Consumer Cooperative of the Central Bureau of Economics of the Ministry of Economic Affairs. This paper is used in a national standard (CNS) Ή specification (210χ2ί) 7 male dragon) \ Amendment page 81. 6. 10,000¾ (Η)

A 6 Π 6 五、發明説明(38) 如表1 9所示,本發明之經滅菌的輸液製劑為無色、透明 、不含沈澱,以及著色及p Η變化受徹底抑制·。即令於8 0 保藏4 8小時後,.製剤仍為無色、透明、且著色舆ρ Η變化受 抑制。如此,顯然己知本發明之輸液製劑具有顯著高度安 定度。 實施例1 4 以實施例.1 3之程序之相同方式獲得輸液製劑,唯表1 S之 電解質組成以表20所示之另一組成置換。使用如此所得之 製劑進行加速保藏試驗。如此,於滅菌後即刻及於δ0Ό保 藏48小時後測量濾液之外觀、箸色度,及pH值。如例13之 輸液製劑之例,本例裂劑顯示頭著高安定度。 (請先閲请背而之注意事項番填筠 装· 經濟部屮央棵準局员工消设合作杜印t 表 20 組 分 潑 度(每 氛 化 m -1 , .9 4 9 g 氛 化 鉀 4 .3 0 2g 硫 酸 镁· 7H,.0 2 .0 5 4 g 萄 糖酸鈣.HiO 6 ,3 5 2 g 蘇 酸 甘油酯二鉀 (50¾) 8 .016g 乙 酸 鈉· 3H3〇 11 .3 4 0 g 硫酸鋅· 7H20 9 . 585mg 寶施例1 5 由79.2g大豆油,11.4g卵黃礎脂,及600g葡萄糖所組成 之混合物以注射甩蒸餾水諝整為總體稹1 0 0 0 n il 及所得 混合物使用曼頓-高林均化機(1 5 Μ - 3 T A、高林公司製造)乳 Ζ.. 'λ 本紙紅度边用中as家規格(21〇父297公龙)降正诗::: 81. 4· 10,〇〇〇張(η) 訂 線. 經濟部屮央標準局EX工消赀合作杜印製 _nj_ 五、發明説明(39) 化。如此所得乳液以2.4倍體積之水稀釋。50nijl容積之玻 璃瓶内饋入如此稀釋後之乳液,並將瓶内空氣以氮氣置換 ,繼以密封。隨後,如此密封後之瑱充以稀乳液之瓶藉由 於115”高壓蒸氣滅菌30分鐘。如此所得製劑於後文中稱 為”加糖脂肪乳液”。此脂肪乳液顯示平均脂肪粒徑為 0 . 1 6 u m 〇 以無菌方式取出2πι义整分之例13所得之含胺基酸類及電 解質類之輸液製劑,並移入15m义容積之無菌聚苯乙烯管 内。其次,以無菌方式取出4ιι艾前述加糖脂肪乳液,並移 入該聚苯乙烯管内,將製劑與乳液混合,繼以密封管。測 量如此所製妥之混合物之混濁度,平均粒徑及外觀之變化 經歴48小時,結果示於表21。此例中,混濁度,以於620 nra之吸光率表示(Ιαπ光學管);而脂肪乳液之平均粒徑偽 以光繞射法測Μ。 表 21 試驗項目 混合後 24小時後 48小時後 混濁度 0.034 0.034 0.036 (請先閱讀背而之注意事項再填窍本頁) 徑 粒 均 平 見 0 外 表 如 見 易 然 質顯 均果 結 示 所 質 均A 6 Π 6 V. Description of the invention (38) As shown in Table 19, the sterilized infusion preparation of the present invention is colorless, transparent, free of precipitation, and coloration and changes in pH are completely suppressed. Even after being stored for 8 to 8 hours at 80, the production was still colorless, transparent, and the change in color and pH was suppressed. As such, it is clear that the infusion preparation of the present invention has a significantly high degree of stability. Example 14 An infusion preparation was obtained in the same manner as the procedure of Example 1.3, except that the electrolyte composition of Table 1 S was replaced with another composition shown in Table 20. The preparation thus obtained was used for an accelerated storage test. In this way, the appearance, color, and pH of the filtrate were measured immediately after sterilization and after 48 hours of storage at δ0Ό. As in the example of the infusion preparation in Example 13, the splitting agent in this example showed high stability. (Please read the notes on the back. Please fill in the package. The staff of the Ministry of Economic Affairs of the Central Bureau of the Ministry of Economic Affairs shall set up a cooperation. Du Yin t Table 20. The composition of each component (m -1, .9 4 9 g per atmosphere) Potassium 4.3 0 2g magnesium sulfate.7H, .0 2 .0 5 4 g calcium gluconate. HiO 6, 3 5 2 g glyceryl threonate dipotassium (50¾) 8.016g sodium acetate. 3H3〇11. 3 4 0 g zinc sulfate · 7H20 9 .585 mg Bao Shi Example 1 5 The mixture consisting of 79.2 g soybean oil, 11.4 g yolk base fat, and 600 g glucose was converted to a total of 10.0 0 n il And the resulting mixture using a Manton-Gorlin homogenizer (15 M-3 TA, manufactured by Gorlin Co., Ltd.) milk z .. 'λ The original redness of the paper is used in the asas specifications (21〇 father 297 male dragon) reduction poems: :: 81. 4 · 10, 000 sheets (η) of the line. Co-printed by EX Engineering Consumers, Bureau of Standards, Ministry of Economic Affairs, Co., Ltd. _nj_ V. Description of the invention (39). The emulsion thus obtained has a volume of 2.4 times Water dilution. A 50nijl volume glass bottle is fed with such diluted emulsion, and the air in the bottle is replaced with nitrogen, and then sealed. Then, the sealed bottle is filled with dilute emulsion Due to 115 "high-pressure steam sterilization for 30 minutes. The preparation thus obtained is hereinafter referred to as" sweetened fat emulsion ". This fat emulsion shows an average fat particle size of 0.16 um. Aseptically taken out of the 2πintegral example 13 The infusion preparation containing amino acids and electrolytes is transferred into a sterile polystyrene tube with a volume of 15m. Secondly, the 4μm Ai sugar-added fat emulsion is taken out aseptically and transferred into the polystyrene tube to mix the preparation with the emulsion , Followed by a sealed tube. The turbidity of the mixture thus prepared was measured, and the average particle size and appearance changed over 48 hours. The results are shown in Table 21. In this example, the turbidity is represented by the absorbance at 620 nra ( Ιαπ optical tube); and the average particle size of the fat emulsion is pseudo-measured by the light diffraction method. Table 21 Test items Turbidity 0.034 0.034 0.036 after 24 hours and 48 hours after mixing (please read the notes before refilling This page) The diameter and particle size are average, see 0.

W 質 均 含 與 其 於 劑 製 液 輸 之 明 發 本 安 之 液 乳 肪 脂 0 破 會 不 後 合 裩 液 溶 之 類 質 解 電 及 6 類 1 酸 。例 基性施 胺定實 備一 製 之 液 輸 之 糖 及i 液 乳 肪 脂 含 本紙尺度边用中国國家楳毕(CNS) ΤΜ規tM2]0x297公¢) 81. 4. 10,000張(H) 五、發明説明(40) A 6 Π 6 66g整分之大豆油,9.5g卵黃磷脂,及500g葡萄糖加入 適量體積水中,混合物使用混合機摄拌,隨後以注射用蒸 餾水調整為總體積1000niil的粗乳液。如此所得粗乳液使 用曼頓-高林均化機(15M-8TA,高林公司製造)乳化,而得 平均粒徑為0.17/i m或以下之乳液。加水至500πι儿整分之 如此所生成之乳液内,將總體積調整為1000m文。如此所 得輸液之組成示於表2 2。 _表 22組 分 大豆油 卵黃磷脂 蕕萄糖注射用蒸餾水 數 量U)334.75 2 5 0·需要量而將總體積調 備 製 之 液 輸 之 類 質 解 電 及 頚 酸 基 胺 含 各 之 質 解 電 及 酸 基 胺 之 示 所 4 2 及 3 2 表 將 下 流 氣 氮 於 (請先閲讀背而之注意事項再塡寫本頁) 經濟部屮央標準扃月工消饨合作社印製 檸 以 液 溶 得 所 ο 内 水 餾 蒸 用 射 注 之 V 0 8 於20 持6. Η 維 Ρ 於為 解整 溶·調 量酸 數檬 本紙张尺度逍用中as家標準(CHS)下4規格(210x297公货) 81, 4. 10,_張(Η) 五、發明説明(41) 表 23 分 濃度 Λ 6 Π 6 (每升) 經濟部中央5$準局Μ工消费合作社印51 L-異白胺酸 L-白胺酸 L-纈胺酸 L-_ 胺酸《HC1 L-蛋胺酸 L-苯基丙胺酸 L-酥胺酸 L-色胺酸' L-精胺酸 L-組胺酸 甘胺酸 L-丙胺酸 L-脯胺酸 L-天冬胺酸 L-絲胺酸 L-酪胺酸 L-麩胺酸 N-乙醛基_L-半胱胺酸 8.000 g 14.000 g 8.000 g 10.000 g 4.000 g 8.000 g 6.000 g 1.200 g 10.500 g 5.000 g 5.300 g 8.500 g 6.000 g 1.500 g 3.000 g 0. 500 g 1.500 g 1. ’lOO g (請先閲讀背而之注意本項#填寫本頁) 裝· ,1Τ 線- / ^紙張尺度边用中a S家楳準(CNS) Ή規格(210父297公放) 81. 6. 10,000張(Η) :'-令';, 隹二 經济部屮央櫺準局员工消许合作杜印31 fs-; 抓年》月1The quality of W contains all of the liquid fats and fats that are intrinsically safe in the preparation of liquid preparations. When broken, it will not dissolve and then dissolve in the liquid, and the 6 types of 1 acids. For example, a basic solution of amines is prepared to prepare a liquid sugar and i liquid fat containing the paper. The paper is used on the side of the paper. China National University of Technology (CNS) ΤM regulations tM2] 0x297 (¢) 81. 4. 10,000 sheets (H) V. Description of the invention (40) A 6 Π 6 66g whole soybean oil, 9.5g egg yolk phospholipid, and 500g glucose are added to the appropriate volume of water, the mixture is mixed with a mixer, and then adjusted to a total volume of 1000niil with distilled water for injection Lotion. The crude emulsion thus obtained was emulsified using a Manton-Gorlin homogenizer (15M-8TA, manufactured by Korin) to obtain an emulsion having an average particle diameter of 0.17 / i m or less. Add water to the entire emulsion produced by 500πι, adjust the total volume to 1000m. The composition of the infusion thus obtained is shown in Table 22. _Table 22 Quantity of distilled water for component soybean oil, yolk phospholipid and dextrose for injection U) 334.75 2 5 0 · Required quantity and the total volume of the prepared liquid is transferred and the qualitative solution and the amido acid group contain each The display of electricity and acid amines 4 2 and 3 2 will list the downstream gas nitrogen (please read the precautions first and then write this page). Dissolve ο Intra-water distillation steam injection V 0 8 held at 20. Η 维 Ρ In order to dissolve and adjust the amount of acid number lemon paper paper standard ass standard (CHS) under 4 specifications ( 210x297 public goods) 81, 4. 10, Zhang (Η) 5. Description of the invention (41) Table 23 Sub-concentration Λ 6 Π 6 (per liter) 5 $ quasi-bureau Μ 工 consumer cooperative printed by the Ministry of Economic Affairs 51 L-iso Leucine L-Leucine L-Valine L-_ Amino Acid "HC1 L-Methionine L-Phenylalanine L-Phenylalanine L-Tryptophan 'L-Arginine L-Group Glycine Glycine L-alanine L-proline L-aspartate L-serine L-tyrosine L-glutamic acid N-acetaldehyde-L-cysteine 8.000 g 14.000 g 8.000 g 10.000 g 4.000 g 8.000 g 6.000 g 1.200 g 10.500 g 5.000 g 5.300 g 8.500 g 6.000 g 1.500 g 3.000 g 0. 500 g 1.500 g 1. 'lOO g (please read the back first and pay attention to this item # fill in this page) install, 1T line-/ ^ Paper-scale side use of a S family support standard (CNS) Ή specification (210 father 297 public release) 81. 6. 10,000 sheets (H): '-order'; Xu Cooperation Du Yin 31 fs-; Catch the Year "Month 1

Γί. M 五、發明説明(42) 分 表 24 濃度 (每升) 氛化鈉 ' 氯化鉀 硫酸鎂 *7Η20 Μ萄糖酸鈐*η2ο 磷酸甘油酯二鉀 (50%) 硫酸鈉 ·3Η20 硫酸鋅· 7Η20 1.949 g 4.302 g 2.054 g 6.352 g 8.016 g 11.340 g 9.585 mg (3)本發明之輸液製劑之滅茵與製備 ^使用具有如第1圖所示之構造的聚丙烯容器,以扣緊拴7 將連通構件6封閉之後,將600ml之.如上程序.(1)所得之含 脂肪乳液及糖之輸注液由0 口 δ注入第一隔間2伴隨著饋人 氮氣,隨後密封開口 8。以類似方式,將300miL之如上程 序(2)所得之含胺基酸類及電解質類之输液由開口 9注入第 二隔間3伴隨蒈搜入氮氣,隨後密封開口 9。如此製妥之容 器1藉由於11 5 高壓蒸氣滅菌3 0 ’分鐘,繼以冷郤至室溫。 滅菌後,由連'通器件6移開扣緊拴7 ,第一及第二隔間2 及3内之输液經由逮通器件6撤底混合而得本發明之輸液製 劑。如此所得輸液製劑之组成示於表2 5。Γί. M V. Description of the invention (42) Sub-table 24 Concentration (per liter) Sodium citrate 'Potassium chloride magnesium sulfate * 7Η20 ΜGarbate * η2ο Dipotassium glycerophosphate (50%) Sodium sulfate · 3Η20 sulfuric acid Zinc · 7Η20 1.949 g 4.302 g 2.054 g 6.352 g 8.016 g 11.340 g 9.585 mg (3) The extinction and preparation of the infusion preparation of the present invention ^ Use a polypropylene container with the structure shown in Figure 1 to fasten the bolt 7 After the communication member 6 is closed, 600 ml of the infusion solution containing fat emulsion and sugar obtained from the above procedure (1) is injected from the 0 port δ into the first compartment 2 with the feeding of nitrogen gas, and then the opening 8 is sealed. In a similar manner, 300 ml of the infusion solution containing amino acids and electrolytes obtained in the above procedure (2) was injected into the second compartment 3 through the opening 9 to search for nitrogen gas, and then the opening 9 was sealed. The container 1 thus prepared was sterilized by autoclaving with 11 5 for 30 minutes and then cooled to room temperature. After sterilization, the fastening bolt 7 is removed from the connecting device 6, and the infusions in the first and second compartments 2 and 3 are withdrawn through the catching device 6 and mixed to obtain the infusion preparation of the present invention. The composition of the infusion preparation thus obtained is shown in Table 25.

MMfc尺度边用中國S家ft準(CNS)IM規格(210父297公使)珍正'/ U> C 81. 6. 10,000¾ (Η) 請 m in 背 而 之 t 事 項 再 裝 訂 線The MMfc scale uses the Chinese S home ft standard (CNS) IM specifications (210 father 297 ambassadors) Zhenzheng '/ U > C 81. 6. 10,000¾ (Η) Please m in the back t item and then re-binding the line

A7 B7 五、發明説明(43 表 25 輸液製 劑 成 實施例16 (每升) 22.OOg 3 . 17g 實施例1 7 (每升) 1 7 . 33g 2 . 49g (請先閲讀背面之注意事項再填寫本頁) rA7 B7 V. Description of the invention (43 Table 25 Infusion preparation into Example 16 (per liter) 22.OOg 3.17g Example 17 (per liter) 1 7.33g 2.49g (Please read the precautions on the back first Fill in this page) r

'1T 經濟部中央標準局員工消費合作社印製 脂肪 大豆油 卵黃磷脂 糖 葡萄糖 胺基酸類 L-異白胺酸 L-白胺酸 L-纈胺酸 L -離胺酸· H C 1 L-蛋胺酸 L-苯基丙胺酸 L-酥肢酸 L-色胺酸 L-精胺酸 L-組胺酸 甘胺酸 L-丙胺酸 L-脯胺酸, L-天冬胺酸, L-絲胺酸· L-酪胺酸, L-麩胺酸, Ν-乙豳基-L-半胱胺酸 1 6 6 . 6 7 g 2 . 67g 4 . 67g 2 . 67g 3 . 33g 1 . 33g 2 . 67g 2 . 0 0 g 0 . 40g 3 . 5 0 g 1 . 6 7 g 1 . 77g 2 . 83g 2 . 0 0 g 0 . 5 0 g 1 . OOg 0 . 17g'1T Ministry of Economic Affairs Central Standards Bureau employee consumer cooperatives printed fat soybean oil egg yolk phospholipid glucosamine amino acids L-isoleucine L-leucine L-valine acid L-lysine · HC 1 L-methionine Acid L-Phenylalanine L-Pulmonary acid L-Tryptophan L-Arginine L-Histidine Glycine L-alanine L-proline, L-aspartic acid, L-filament Amino acid · L-tyrosine, L-glutamic acid, Ν-acetoxy-L-cysteine 1 6 6. 6 7 g 2. 67g 4. 67g 2. 67g 3. 33g 1. 33g 2 .67g 2. 0 0 g 0. 40g 3. 5 0 g 1. 6 7 g 1. 77g 2. .83g 2. 0 0 g 0. 5 0 g 1. OOg 0. 17g

122.OOg 2 . 67g 4 . 67g 2 . 67g 3 . 33g 1 . 33g 2 . 67g 2 . OOg 0 . 40g 3 . 5 0 g 1 . 6 7 g 1 . 77g 2 . 83g 2 . OOg 0 . 5 0 g 1 . OOg 0 . 17g 0 . 5 0 g 0 . 37g 本紙張尺度適用中國國家揉準(CNS ) A4规格(210X297公釐) 修正賓 320563 Λ 6 Π 6 五、發明説明(44) 表 25 輸 液 製 劑 組 成 實施例 16 實施例 17 (每升)' (每升 ) 電解質類· 鈉 38.89 mEq 38-89 mEq 鉀 30.00 mEq 30.00 mEq 鈣 9.44 mEq 9.44 mEq m 5.56 mE 5.56 mEq 氣 48.60 mEq 45.17 iuEq 磷 5.37 mEq 7.17 mEq 鋅 11.11 μιποί 11.11 μιηοΐ 其他成份 _檸樣酸 1.401 g 1.401 g (請先閱請背而之注意事項#場舄本頁) 經濟部屮央榀準局工消仲合作杜印製 (4 )輸液製劑之安定度試驗 如上程序(3)所得之本發明之輸液製劑儲存於25Ό經歴 一週,及測量儲存期間之外觀,平均脂肪粒徑及混濁度之 變化。結果示於表2 6。此例中,藉由重複前述程序獲得對 照輸液製劑,但將3 0 0 b义注射用.蒸餾水封於第二隔間3内 。藉光繞射法測量脂肪乳液之平均粒徑,混濁度以於620 nm之吸光率表示(lcm光學管)。 本紙張尺度逍用中困Η家標準(CNS)甲4規格(210x297公龙) 81. 6. 10,000張⑻ Π 6 五、發明説明(45) ^ 0 筘螽闲. 李趣 书甚筇商. ¾糫遄皿 (請先閲讀背而之注念事項洱填寫本頁) 經濟部中央標準局员工消伢合作杜印製122.OOg 2.67g 4.67g 2.67g 3.33g 1.33g 2.67g 2.OOg 0.40g 3.50 0g 1.6.6 7g 1.77g 2.83g 2.OOg 0.50 g 1. OOg 0. 17g 0. 5 0 g 0. 37g The paper size is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) Modified Bin 320563 Λ 6 Π 6 V. Description of the invention (44) Table 25 Infusion Formulation Composition Example 16 Example 17 (per liter) '(per liter) Electrolytes · Sodium 38.89 mEq 38-89 mEq Potassium 30.00 mEq 30.00 mEq Calcium 9.44 mEq 9.44 mEq m 5.56 mE 5.56 mEq Gas 48.60 mEq 45.17 iuEq Phosphorus 5.37 mEq 7.17 mEq Zinc 11.11 μιποί 11.11 μιηοΐ Other ingredients _ citric acid 1.401 g 1.401 g (please read the back and forth notes # 场 舄 this page) The Ministry of Economic Affairs, the Central Bureau of Industry and Commerce, the Central Committee of the Ministry of Economic Affairs and Industry Cooperative Printing (4) The stability test of the infusion preparation The infusion preparation of the present invention obtained by the procedure (3) above was stored at 25 ° C for one week, and the appearance, average fat particle size and turbidity change during storage were measured. The results are shown in Table 26. In this example, the reference infusion preparation was obtained by repeating the aforementioned procedure, but 300 B was injected for the purpose of injection. Distilled water was sealed in the second compartment 3. The average particle size of the fat emulsion is measured by the light diffraction method, and the turbidity is expressed by the absorbance at 620 nm (lcm optical tube). The size of this paper is easy to use. The standard of CN Standards (CNS) A 4 specifications (210x297 male dragons) 81. 6. 10,000 sheets ⑻ Π 6 V. Description of the invention (45) ^ 0 識 螽 闲. ¾Yushi (please read the back-to-back notes first and fill in this page) Employees from the Central Bureau of Standards of the Ministry of Economic Affairs cooperated to print

0.034 0.031 0.031 0.03S 0·16 μ3 0.16 μιη 0·16 μιη 0.16 μ3 0.0340.034 0·030 0.040 0.1α1μ3σ,.ισιμιη o.lcni ρισιι e ^ Φ 0 24、> 葫菸 4 8、>1¾东 一 遄菸 裝- 、·3Τ 線. 私紙張尺度逍用中國國家揉'準(CHS)肀4規格(210x29’/公;tf) 81. 6. 10,〇〇〇張(Η) ' λ% U'h” 經濟部屮央棵準局A工消伢合作杜印製 五、發明説明(46) 如表2 6所示,本發明製劑於保藏期間,外觀,粒徑或混 濁度皆無任何變化,如此證實本發明之製剤之安定性.。 實施例1 7 依據例1 6之程序(1)裂備具有下表27所示之組成之輸液。 至— 27 _ 組 分 數 量(g) 大豆油 卵黃磷脂 葡萄糖 注射用蒸餾水 26 3.74 183 需要量而將總髏積謌 整至1000m文 藉由重復實施例1 6之方法獲得一種輸液製劑,唯使用表 27之含糖脂肪乳液取代表22之脂肪乳液,及使用下表28所 示之電解質溶液取代表2 4之電解質溶液。如此所得输液製 劑之组成示於表2 5。 表 23 組 分 漤度 (每升) 氣化鈉 1 . 9 4 9,g 氮化鉀 3 . 5 0 0 g 硫酸鎂·7Η2〇 2.054g 菊萄瑭酸鈣· H20 ^ 6.352g 谦酸甘油酯二鉀(5 0 % ) 1 0 . 6 8 S g 乙酸鈉· 3H,0 11.340g ' 硫酸鋅.7H 2 Ο 9 . 5 8?5 mg (請先閱请背而之泣意事項#填窍本頁) 裝· 订_ 線 t紙張尺度边用中酉a家榣準(CNS) Ή規格(2]0X297公龙) 珍 費 81. 4. 10,000flL(H) A 6 Π 6 五、發明説明(47) 如此製妥之輸液製劑之安定度試驗傺以如同例16之相同 方式進行。發現如同例16之輸液製劑般,本製劑之安定度 卓越。 ^ 實施例28 將適量體積注射用蒸餾水加入6 6 g大豆油與9 . 5 g卵黃磷 脂所組成之混合物内,所得混合物使用混合機攪拌,隨後 以注射用蒸餾水調整為總體積1 0 0 0IHJI而得粗乳液。如此 所得粗乳液使用曼頓-高林均化機(15M-8TA,高林公司製 造)乳化而得脂肪乳液。5 0 0 in义整分之所得乳液與2 5 0 g葡 萄糖混合,混合物總體積以注射用蒸餾水調整為1 0 0 0 m义 。如此所得脂肪乳液之組成示於表2 9。 _M_2_9_ 組 _ 大豆油 卵黃磷脂 葡萄糖 注射用蒸餾水 數 量(s) 33 • 75 (請先閲讀背而之注意事項#蜞窩本頁) 經濟部屮央櫺準局员工消仲合作社印製 250 將總體積調整至1 0 0 0 m义 所需之量 藉由重複例16之方法獲得一種輸液製劑,唯使用表29之 脂肪乳液取代表22之脂肪乳液。 以例16之相同方式進行如此所製妥之輸液製劑之安定度 試驗。如同例16之輸液製劑之例般,本製劑可得卓越安定 性。 雖已就其細節並參照待定例說明.衣發明,但業界技藝精 卜紙张尺度边用中a S家榀準(CNS)T4規格(210x297公;《:) 81_ 4. 10,000張(H) A 6η 6 五、發明説明(48)湛人士顯然易知,可在未背離本發明之精髓與範圍下作成 多種變化與修改。 (請先閲讀背而之注意事項再填窍本頁) 裝* 線· { 經濟部屮央榣準局貝工消仰合作杜印製 良紙張尺度边用中8困家標準(CNS)甲4規格(210x297公龙) 81. 4. 10,⑽乐(H)0.034 0.031 0.031 0.03S 0 · 16 μ3 0.16 μιη 0 · 16 μιη 0.16 μ3 0.0340.034 0 · 030 0.040 0.1α1μ3σ, .ισιμιη o.lcni ρισιι e ^ Φ 0 24, > Huyan 4 8, > 1¾ east One cigarette pack-, · 3Τ line. Private paper scales are used in China's national rubbing standard (CHS) 4 specifications (210x29 '/ male; tf) 81. 6. 10, 〇〇〇 张 (Η)' λ% U'h ”A copy of the work of the Ministry of Economic Affairs and the Bureau of Industry and Commerce A. The printing of the invention 5. Description of the invention (46) As shown in Table 26, there is no change in the appearance, particle size or turbidity of the preparation of the present invention during storage Thus, the stability of the preparation method of the present invention is confirmed .. Example 1 7 According to the procedure of Example 16 (1) prepare an infusion solution with the composition shown in Table 27 below. To — 27 _ number of components (g) soybean oil Distilled water for egg yolk phospholipid and glucose injection 26 3.74 183 The total volume was adjusted to 1000 m as required. An infusion preparation was obtained by repeating the method of Example 16 except that the sugar-containing fat emulsion of Table 27 was used instead of the fat emulsion of Table 22 , And use the electrolyte solution shown in Table 28 below to replace the electrolyte solution in Table 24. The infusion system thus obtained The composition is shown in Table 25. Table 23 Component concentration (per liter) Vaporized sodium 1.9 4 9, g Potassium nitride 3. 5 0 0 g Magnesium sulfate · 7Η2〇2.054g Calcium chrysanthenate · H20 ^ 6.352g dipotassium glycerol dibasic acid (50%) 1 0. 6 8 S g sodium acetate · 3H, 0 11.340g 'zinc sulfate. 7H 2 Ο 9. 5 8? 5 mg (please read the back first And weeping intentions #Fill in this page) Binding · Order _ Line t paper size side use Zhongyou a home standard (CNS) Ή specification (2) 0X297 male dragon) Precious fee 81. 4. 10,000flL (H) A 6 Π 6 V. Description of the invention (47) The stability test of the infusion preparation thus prepared was carried out in the same manner as in Example 16. It was found that the stability of this preparation is excellent as infusion preparation of Example 16. ^ Examples 28 Add an appropriate volume of distilled water for injection to a mixture of 66 g of soybean oil and 9.5 g of egg yolk phospholipid. The resulting mixture is stirred using a mixer, and then adjusted to a total volume of 100 IHJI with distilled water for injection to obtain a crude emulsion. The coarse emulsion obtained in this way is emulsified using a Manton-Gauline homogenizer (15M-8TA, manufactured by Kobayashi) to obtain a fat emulsion. 5 0 0 in the resulting emulsion and 2 5 0 g of glucose is mixed, and the total volume of the mixture is adjusted to 100 m with distilled water for injection. The composition of the fat emulsion thus obtained is shown in Table 29. _M_2_9_ Group_ Soybean Oil Yolk Phospholipid Glucose Injectable Distilled Water Quantity (s) 33 • 75 (please read the back-to-back precautions # 蜞 窝 this page) printed by the Ministry of Economic Affairs quasi-bureau employee Xiaozhong Cooperative 250 will be the total volume Adjust to the required amount of 100,000 m by repeating the method of Example 16 to obtain an infusion preparation, only using the fat emulsion of Table 29 instead of the fat emulsion of Table 22. The stability test of the infusion preparation thus prepared was conducted in the same manner as in Example 16. As in the case of the infusion preparation of Example 16, this preparation can achieve excellent stability. Although the details have been explained with reference to the pending examples, the invention of the clothing, but the industry's technical skills, paper-scale edge use in China S standard (CNS) T4 specifications (210x297 ;; :) 81_ 4. 10,000 sheets (H) A 6η 6 V. Description of the Invention (48) It is obvious to the Zhan person that various changes and modifications can be made without departing from the essence and scope of the present invention. (Please read the precautions first and then fill in this page) Install * Line Specifications (210x297 male dragon) 81. 4. 10, ⑽ Le (H)

Claims (1)

86, 6. 20 修正本 六、申請專利範圍 1 . 種 包 括 糖 胺 基 酸類 組 合 物 9 其 中 該 組 合 物所 式 9 或 圼 m 鹽 形 式 9 並K 其 中 該 組 合 物 包 括 下 列各 脂 肪 5 -50 乳 化 劑 0 .5 -10 糖 50 -250 L- 異 白 胺 酸 0. 5-5 L-白 胺 酸 0 . 5-7 L- 纈 胺 酸 0 . 5-5 L- 離 胺 酸 0 . 5-7 L- 蛋 胺 酸 0 . 1-4 L- 苯 基 丙 胺 酸. 0 . 3-5 L- 酥 胺 酸 0 . 3-5 L- 色 胺 酸 0 . 1-1 L- 精 胺 酸 0 . 3-7 組 胺 酸 0. 2-3 * 甘 胺 酸 0 . 2-3 L _ .‘ -· * • ιί· 胺 酸 0 . 3-5 L- 脯 胺 酸 $ 0 . 2-5 L- 天 冬 胺 酸 9 0 .03-2 L- 絲 胺 酸 9 0 . 2-3 L- 賂 胺 酸 » 0 .03-0. (請先^讀背面之注意事項再填寫本頁) __1— -.- h I L_ — II--^ I . 订 紙. 經濟部中央標準局貝工消費合作社印菜 、電解質類,及脂肪轧液之输 含之磷呈多元酵或糖之磷酸酯 有櫬酸將pH調整為5.0至8.0, 組分: g/ H g/ β g/ a g/ ϋ g/ a g/ a g/ a g / n g/ a g / fi g/ ϋ g /1 g/ n g/ n g/ g/ fl g / R g / il 5g/ a -1- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) A8 B8 C8 D8 六、申請專利範圍 經濟部中央揉準局貝工消費合作社印裝 L- 麩 胺 酸 0 .03-2 g/ H L - 半 胱 胺 酸 0 .03-1 IB E q / 納 15-60 ffl E q / 11 鉀 10-50 IB E q / il 鈣 3-15 HI E q / fi. 鎂 2-10 IS E q / fl 氛 0-80 ffl E q / il m 1-15 lfl E q / ft ; 及 鋅 0-30 U ffi 0 1 / fl. 其 中 所 述 脂 肪 為 大 豆油; 所述乳化劑為 選自 卵 黃 磷 脂, 氫 化 卵 黃 磷 脂 大 豆 磷脂, 氫化大豆磷脂 ,及 非 雄 子 界面 活 性 劑 中 之 至 少 一 員 ;及所 述作為糖源之 遢原 糖 為 葡 萄糖 及 /或甘油&lt; ) 2 . 如 請 專 利 範 圍 第1項之輸液組合 物 其中所述脂肪 乳 液 之 平 均 粒 徑 為 0. 13〜0 . 1 7 w BI ° 3 . 如 Φ 請 專 利 範 画 第1項之輸液組合 物 其中所逑有機 酸 為 揮 m 酸 0 4 . 一 種 含 脂 肪 乳 液 及糖之 輸液组合物, 其中 脂 肪 之 含董 由 0 . 1 至 30¾ (V /V ) 乳化劑之含量由0 . 01 至 10¾ (W /V ) 及 糖 之 含 Μ 由 5 至 60¾ (W / v ),Μ及該脂肪 乳液之平均粒徑為 0 . 13 0 . 17 U is 其中所述脂肪為大豆 油 所述,乳化劑為 選 白 卵 黃 磷 脂 氫 化 卵黃磷 脂,大豆磷脂 ,氫 化 大 豆 磷脂 及 非 離 子 界 面 活 性 劑中之 至少一員 及 所述 作 為 糖 源之 糖為或葡萄耱及/或甘油。 (請先閲讀背面之注意Ϋ項再填寫本頁) -裝· ,tT 線 本紙張尺度逋用中國國家橾率(CNS〉A4規格(210X297公釐) 一 2- ABCD 320563 七、申請專利範圍 5.—種含胺基酸類及電解質類之輸液組合物,其中多元 酵或糖之磷酸酯或酯a係作為磷來源及該組合物之ph係使 用選自擰樣酸,乳酸,蘋果酸*葡萄糖酸*顒丁烯二酸, 及丙二酸中之至少一種有機酸調整為5.0至8.0,又其中該 組合物包含總虽為1至15¾之選自下列之胺基酸: L-異白胺酸 L-白胺酸 L-纈胺酸 L-離胺酸 L-蛋胺酸 L-苯基丙胺酸 L-酥胺酸 L-色胺酸 L-精胺酸 L-組胺酸 甘胺酸 L-丙胺酸 L-腩胺酸 L-天冬胺酸 L-絲胺酸 L-賂胺酸 L-麩胺酸 N-乙醢基-L-半胱胺酸; 以及下列電解質:50至50至180mEq/ll納,40至135姐έ&lt;ϊ/ί! 本紙張尺度適用中國國家揉準(CNS ) Α4規格(210乂297公釐) (請先閱讀背面之注意事項再填寫本頁) 裝. 經濟部中央標準局貝工消費合作社印製 -3- 320563 A8 B8 C8 D8 六、申請專利範圍 鉀,1 0至5 0 b E g / ϋ鈣,5至3 0道E q / α鎂,0至2 2 5雇E q / α氛 ,3至 40mEci/il 碟及 0 至 100/i ιηοΐ/ϋ 梓。 參 及 酸 胺 4 組 第L-圍自 範選 利種 專 一 請少 申至 。 如含劑 6.包衝 又緩 物 合 組 該 中 其 物 合 組 液 輪 之 項 之 中 烷 甲 基 胺 \lx 基 甲 羥 法 方 之 液 乳 肪 脂 之W 用17 養0. 營 ~ 供13 備0. 製為 cofi sc 種徑 1 粒 7.均 平 及Μ 及 油 甘 有 之該 液, 乳糖 肪萄 脂葡 該或 肪 脂 將0. : 由 括到 包得 法以 方 - 至 Μ^ 0 S &amp; 到 ® 乳 \1/ 糖/V 萄(W 葡5¾ 或至 // 1 及ο. 油ο 甘 及 劑 化 乳 /IV % 肪 旨 B 液 乳 粗 備 製 Μ V)物 W/合 以混 70該 至拌 30攪 及 及 油 甘 物 合 混 之 成 組 糖 萄 葡 或 及 Μ (請先閲讀背面之注意事項再填寫本頁) I Mi I - I --&quot;- - - - - - I - -- : I ^ I . 至 述化 直 所氫 液 ., , 乳 油脂 粗 豆磷。 化 大豆員 乳,為大一 法 β 肪,少 化 a 脂脂至 乳17述磷之 壓0.所黃中 高? 中卵劑 藉13其化性 0.氫活 為 變 度 粒 均 平 之 液 乳 肪 脂 , 面 脂界 磷子 黃離 卵非 自及 選- 為脂 劑磷 化豆 乳大 訂 線 經濟部中央標準局貝工消费合作社印装 萄 二 葡 含 ’ 與酸 液果 乳蘋 肪 , 脂酸 將乳 括, 包酸 ,0 法擰 方 自 之選 液於 乳, 肪液 脂溶 定 之 安子 SB it 種 纗 一 靥 8 金 價 合 混 成 生 所 二 使 烯以 丁 , 顒合 , 混 酸下 糖在 酸 二 丙 及 酸 存乳 鹽肪 其脂 及該 酸中 i 機 有 CK 種 1 為 少值 至PH 之 之 中物 其 8 至 5 油甘 豆或 大U } 及 /V糖 (¥萄 0¾葡 3之 至 } 1 V • // o W 含 % 包60 液至 至 5 及 劑 化 乳 本紙張尺度逍用中國國家梂準(CNS ) A4规格(210 X 297公釐) 一4 一86, 6. 20 Amend this Sixth, the scope of patent application 1. Species include glycosamino acid composition 9 wherein the composition is represented by formula 9 or salt form 9 and K where the composition includes the following fats 5-50 emulsified Agent 0.5 -10 Sugar 50 -250 L-isoleucine 0.5-5 L-leucine 0.5.5-7 L-valinic acid 0.5-5 L-ionic acid 0.5.5- 7 L-Methionine 0. 1-4 L-Phenylalanine 0. 3-5 L-Glutamine 0. 3-5 L-tryptophan 0. 1-1 L-arginine 0 3-7 histidine 0.23- * glycine 0. 2-3 L _. '-· * • ιί · amino acid 0. 3-5 L- proline $ 0. 2-5 L- Aspartic acid 9 0 .03-2 L- Seric acid 9 0. 2-3 L-Broninoic acid »0 .03-0. (Please ^ Read the notes on the back before filling this page) __1—- .- h I L_ — II-^ I. Ordering paper. In the export of vegetables, electrolytes, and fat rolling liquid of the Central Standards Bureau of the Ministry of Economic Affairs, the phosphorus content of the phosphate is multi-enzyme or sugar phosphate. Adjust the pH 5.0 to 8.0, composition: g / H g / β g / ag / ϋ g / ag / ag / ag / ng / ag / fi g / ϋ g / 1 g / ng / ng / g / fl g / R g / il 5g / a -1- This paper scale is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) A8 B8 C8 D8 VI. Scope of Patent Application The Central Ministry of Economic Affairs of the Ministry of Economic Affairs Beigong Consumer Cooperative Printed L-Glutamine Acid 0.03-2 g / HL-Cysteine 0.03-1 IB E q / sodium 15-60 ffl E q / 11 potassium 10-50 IB E q / il calcium 3-15 HI E q / fi . Magnesium 2-10 IS E q / fl atmosphere 0-80 ffl E q / il m 1-15 lfl E q / ft; and zinc 0-30 U ffi 0 1 / fl. Where the fat is soybean oil; The emulsifier is at least one member selected from the group consisting of egg yolk phospholipid, hydrogenated egg yolk phospholipid, soybean phospholipid, hydrogenated soybean phospholipid, and non-androgen surfactant; and the raw sugar as the sugar source is glucose and / or glycerol &lt;) 2 . If the patent scope first Item infusion composition wherein the average particle size of the fat emulsion is 0.13 ~ 0.1 7 w BI ° 3. For example, Φplease patent the first infusion composition of item 1 in which the organic acid used is sulfonic acid 0 4. An infusion composition containing fat emulsion and sugar, wherein the fat content is from 0.1 to 30¾ (V / V), the emulsifier content is from 0.01 to 10¾ (W / V), and the sugar contains M From 5 to 60¾ (W / v), the average particle size of M and the fat emulsion is 0.13 0.17 U is where the fat is soybean oil, the emulsifier is selected white egg yolk phospholipid hydrogenated egg yolk phospholipid, soybean At least one of the phospholipid, hydrogenated soybean phospholipid and nonionic surfactant and the sugar as the sugar source is grapevine and / or glycerin. (Please read the note Ϋ on the back first and then fill out this page)-Installed, tT line paper size standard Chinese national rate (CNS> A4 specification (210X297 mm) 1 2- ABCD 320563 VII. Patent application scope 5 .—An infusion composition containing amino acids and electrolytes, in which the phosphate or ester a of polyacrylase or sugar is used as the source of phosphorus and the ph of the composition is selected from the group consisting of spiro-like acid, lactic acid, malic acid * glucose The at least one organic acid of acid * oxalic acid and malonic acid is adjusted to 5.0 to 8.0, and wherein the composition contains an amino acid selected from the following although it is always 1 to 15¾: L-isoleucine Acid L-Leucine L-Valine L-Iminine L-Methionine L-Phenylalanine L-Phenylalanine L-Tryptophan L-Arginine L-Histidine Glycine L-Alanine L-Menine L-Aspartic acid L-Serine L-Brucine L-Glutamic acid N-Acetyl-L-cysteine; and the following electrolytes: 50 to 50 To 180mEq / ll, 40 to 135 sisters <ϊ / ί! This paper size is suitable for China National Standard (CNS) Α4 specifications (210 to 297 mm) (please read the precautions on the back before filling this page) Printed by Beigong Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs -3- 320563 A8 B8 C8 D8 6. Patent application Potassium, 10 to 5 0 b E g / ϋ calcium, 5 to 30 E q / α magnesium , 0 to 2 2 5 hire Eq / α atmosphere, 3 to 40mEci / il dish and 0 to 100 / i ιηοl / ϋ Zi. Participate in acid amine group 4th L-Wai self-selection, please select less If the agent contains 6. Baochongyoubuhehe group, in the item of the liquid wheel of the compound group, the alkyl methyl amine \ lx liquid of the methylmetholone formula milk fat is used to raise 17 with 0. 营 ~ For 13 preparations 0. The system is made of cofi sc seed diameter 1 grain 7. The liquid is even and M and olean, lactose, fat, fat, fat, or fat will be 0. ^ 0 S &amp; to® milk \ 1 / sugar / V grapes (W Portuguese 5¾ or to // 1 and ο. Oil ο sweetened with milk / IV% fatty milk B liquid milk crude preparation MV) W / Combined 70 to 30, mixed with oil, sugar, and sugar, and mixed sugar grapes or M (please read the notes on the back before filling this page) I Mi I-I-&quot;-- ----I--: I ^ I. To Shuhua Zhisuo Hydrogen Liquid.,, Milk Fat Crude Soya Phosphorus. Soybean milk, the first-year method of β fat, less fat a milk fat to milk 17 phosphorus pressure 0. So yellow high? The medium egg agent has 13 chemical properties of 0. Hydrogen activity is the liquid milk fat that changes the level of the grain, and the yellow fat is not selected and selected. It is the central standard of the Ministry of Economy. Printed by the Bureau Cooperative Consumer Cooperative Co., Ltd. Grape edulis' with acid liquid, fruit milk and apple fat, fatty acid including milk, including acid, 0 method to choose liquid from milk, fat liquid fat soluble Anzi SB it species A compound of 8 gold valences is mixed with dibutylene and diethylene, mixed with acid, sugar in acid dipropylene and acid stored in milk and its fat, and in this acid, there are CK species 1 which is less than PH value. For its 8 to 5 oil sugar beans or large U} and / V sugar (¥ Grape 0¾ Portuguese 3 to} 1 V • // o W Containing 60 sachets up to 5 and formulated milky paper size Happy Use China National Standard (CNS) A4 specification (210 X 297 mm) One 4 One
TW081103293A 1991-04-26 1992-04-25 TW320563B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP12486691 1991-04-26
JP12486391 1991-04-27
JP12473991 1991-04-28
JP03209947A JP3097196B2 (en) 1991-07-26 1991-07-26 Stabilization of fat emulsion
JP3222031A JP2950348B2 (en) 1991-04-27 1991-08-06 Fat emulsion and method for producing the same

Publications (1)

Publication Number Publication Date
TW320563B true TW320563B (en) 1997-11-21

Family

ID=51567010

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081103293A TW320563B (en) 1991-04-26 1992-04-25

Country Status (1)

Country Link
TW (1) TW320563B (en)

Similar Documents

Publication Publication Date Title
WO1995028906A1 (en) Transfusion container, transfusion preparation, and comprehensive vitamin-containing high-calorie transfusion preparation
ES2313782T3 (en) COMPLETE NUTRITIONAL ENTERIC FORMULA OF LOW PH.
US6129925A (en) Container filled with infusion liquids and infusion preparation
JP2004520065A (en) Hypoglycemic reaction composition
EP0671166B1 (en) Nutrient-supplying infusion
MXPA01012305A (en) Compositions containing creatine in suspension.
TWI603747B (en) Infusion preparation
JP2010148453A (en) Bitterness masking agent for chlorogenic acid
TW200520695A (en) Packaged beverages
TW320563B (en)
EP0988857B1 (en) Nutrient infusion preparation
JP2006045216A (en) Zinc-containing composition for oral administration
ES2372467T3 (en) IMMUNONUTRITIONAL COMPOSITION.
JP2006306847A (en) Copper compound-incorporated composition
JP5355809B1 (en) Beverage
JP2006306846A (en) Copper compound-incorporated composition
JP4717170B2 (en) Nutritional infusion preparation
AU2007294261B2 (en) Liquid composition for prevention and/or treatment of different bone metabolic diseases, uses thereof, and preparation process therefore
KR101736654B1 (en) A liquid suspension composition comprising branched chain amino acids and a preparation method thereof
JPH0532541A (en) Stabilization of fat emulsion
JP3364932B2 (en) Infusion container
JP3456536B2 (en) Infusion preparation
JP3430965B2 (en) Stabilized fat emulsion containing solution
KR890001564B1 (en) A process for the production of a stabilized ginseng drink
JP2002097141A (en) Aqueous solution of vitamin b